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Background: The prognosis of early-onset pre-eclampsia (before 34 weeks’ gestation) is variable.
Accurate prediction of complications is required to plan appropriate management in high-risk women.
Objective: To develop and validate prediction models for outcomes in early-onset pre-eclampsia.
Design: Prospective cohort for model development, with validation in two external data sets.
Setting: Model development: 53 obstetric units in the UK. Model transportability: PIERS (Pre-eclampsia
Integrated Estimate of RiSk for mothers) and PETRA (Pre-Eclampsia TRial Amsterdam) studies.
Participants: Pregnant women with early-onset pre-eclampsia.
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Sample size: Nine hundred and forty-six women in the model development data set and 850 women
(634 in PIERS, 216 in PETRA) in the transportability (external validation) data sets.
Predictors: The predictors were identified from systematic reviews of tests to predict complications in
pre-eclampsia and were prioritised by Delphi survey.
Main outcome measures: The primary outcome was the composite of adverse maternal outcomes
established using Delphi surveys. The secondary outcome was the composite of fetal and neonatal
complications.
Analysis: We developed two prediction models: a logistic regression model (PREP-L) to assess the overall
risk of any maternal outcome until postnatal discharge and a survival analysis model (PREP-S) to obtain
individual risk estimates at daily intervals from diagnosis until 34 weeks. Shrinkage was used to adjust for
overoptimism of predictor effects. For internal validation (of the full models in the development data) and
external validation (of the reduced models in the transportability data), we computed the ability of the
models to discriminate between those with and without poor outcomes (c-statistic), and the agreement
between predicted and observed risk (calibration slope).
Results: The PREP-L model included maternal age, gestational age at diagnosis, medical history, systolic
blood pressure, urine protein-to-creatinine ratio, platelet count, serum urea concentration, oxygen
saturation, baseline treatment with antihypertensive drugs and administration of magnesium sulphate.
The PREP-S model additionally included exaggerated tendon reflexes and serum alanine aminotransaminase
and creatinine concentration. Both models showed good discrimination for maternal complications, with an
optimism-adjusted c-statistic of 0.82 [95% confidence interval (CI) 0.80 to 0.84] for PREP-L and 0.75
(95% CI 0.73 to 0.78) for the PREP-S model in the internal validation. External validation of the reduced
PREP-L model showed good performance with a c-statistic of 0.81 (95% CI 0.77 to 0.85) in PIERS and 0.75
(95% CI 0.64 to 0.86) in PETRA cohorts for maternal complications, and calibrated well with slopes of
0.93 (95% CI 0.72 to 1.10) and 0.90 (95% CI 0.48 to 1.32), respectively. In the PIERS data set, the reduced
PREP-S model had a c-statistic of 0.71 (95% CI 0.67 to 0.75) and a calibration slope of 0.67 (95% CI 0.56
to 0.79). Low gestational age at diagnosis, high urine protein-to-creatinine ratio, increased serum urea
concentration, treatment with antihypertensive drugs, magnesium sulphate, abnormal uterine artery
Doppler scan findings and estimated fetal weight below the 10th centile were associated with fetal
complications.
Conclusions: The PREP-L model provided individualised risk estimates in early-onset pre-eclampsia to plan
management of high- or low-risk individuals. The PREP-S model has the potential to be used as a triage
tool for risk assessment. The impacts of the model use on outcomes need further evaluation.
Trial registration: Current Controlled Trials ISRCTN40384046.
Funding: The National Institute for Health Research Health Technology Assessment programme.
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Plain English summary
P re-eclampsia is a disorder in pregnancy, characterised by raised blood pressure and protein in the urine.When it occurs before 34 weeks of pregnancy (early onset), it causes serious complications for the
mother and baby. The only known cure for pre-eclampsia is delivery of the baby. There is a lack of
sufficient evidence regarding the ability of tests to correctly predict complications to the mother or baby to
inform management.
The PREP (Prediction of Risks in Early-onset Pre-eclampsia) study aims to provide estimates of risks faced by
mothers, using tests that are routinely performed in the NHS.
We developed two models. The first model (PREP-L) provided overall individual risk estimates from
diagnosis of early-onset pre-eclampsia until discharge. The second model (PREP-S) provided risk estimates
at various time points from diagnosis until 34 weeks of pregnancy. The models’ performance was assessed
in populations outside the UK (Canada and the Netherlands).
A total of 946 women with early-onset pre-eclampsia from 53 hospitals in the UK participated in the
study. For 82% of the women participating, the PREP-L model accurately predicted those mothers who will
develop complications. The PREP-S model predicted accurately in 76% of women. The PREP-L model
performed similarly in non-UK populations. Both models showed that the results could be generalised in
an external population. Further studies are needed to assess the impact of the models’ use in improving
outcomes for the mother and baby.
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Scientific summary
Background
Women with early-onset pre-eclampsia (before 34 weeks’ gestation) are at high risk of maternal and fetal
complications. Early identification of pregnancies at high risk is required to plan transfer of mothers to a
tertiary care unit, commence intense monitoring and administer corticosteroids for fetal lung maturity.
Objectives
Primary
To develop prediction models to assess the overall risk of composite maternal outcomes in women with
early-onset pre-eclampsia by postnatal discharge and at various time points after the diagnosis of the
condition and to validate the performance of these prediction models in external data sets for assessment
of transportability.
Secondary
To assess the predictive value of baseline maternal and fetal characteristics and tests for fetal and neonatal
complications at birth and by discharge.
Methods
We developed and externally validated two prediction models: a logistic model (PREP-L) to assess the risk
of any maternal complication until postnatal discharge and a survival analysis model (PREP-S) to predict the
risk of composite maternal outcome at various time points after diagnosis and until 34 weeks’ gestation.
Development of the models
Data source
We undertook a prospective observational study [Prediction of Risks in early-onset Pre-eclampsia (PREP)].
Consecutive eligible women with early-onset pre-eclampsia were recruited from 53 secondary and tertiary
care maternity units in the UK. Pregnant women presenting with uncomplicated early-onset pre-eclampsia
before 34 weeks’ gestation were recruited to the study if they satisfied the following inclusion criteria:
l new-onset pre-eclampsia, defined as new-onset hypertension [systolic blood pressure (BP) of
≥ 140 mmHg or diastolic BP of ≥ 90mmHg on two occasions between 4 and 6 hours apart] after
20 weeks of pregnancy and new-onset proteinuria (2+ or more on a urine dipstick or urine protein-to-
creatinine ratio (PCR) of > 30mg/mmol or 300 mg of protein excretion in 24 hours)
l superimposed pre-eclampsia diagnosed in women with chronic hypertension before 20 weeks’
gestation and new-onset proteinuria. In women with significant proteinuria before 20 weeks’
gestation, we defined superimposed pre-eclampsia as elevated serum alanine aminotransferase
concentration (> 70 units per litre) or worsening hypertension (either two diastolic BP measurements of
at least 110 mmHg 4 hours apart or one diastolic BP measurement of at least 110 mmHg if the woman
had been treated with an antihypertensive drug) and one of the following: increasing proteinuria,
persistent severe headaches or epigastric pain
l haemolysis, elevated liver enzymes, low platelets (HELLP) syndrome
l one episode of eclamptic seizures with no hypertension or proteinuria.
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Additionally, we recruited women with suspected pre-eclampsia, with new-onset hypertension and
1+ proteinuria on a urine dipstick. Only those women whose diagnosis of pre-eclampsia was confirmed
subsequently with significant proteinuria (PCR > 30 mg/mmol or 24-hour urine protein concentration
> 300 mg) were included in the primary models.
Candidate predictors
We evaluated the predictive ability of tests that were routinely performed in women with pre-eclampsia.
We identified 22 maternal and 27 fetal predictors a priori through systematic reviews and Delphi surveys
for their association with adverse outcomes and their availability in the UK NHS.
We evaluated the following:
l maternal characteristics including age, gestation at diagnosis of pre-eclampsia and number of fetuses
in pregnancy
l medical history including pre-existing hypertension, renal disease, diabetes mellitus, autoimmune
disease and/or history of pre-eclampsia in previous pregnancies
l symptoms including headache and/or visual disturbance, epigastric pain, nausea and/or vomiting,
chest pain and dyspnoea
l bedside examination findings and tests including BP, clonus, tendon reflex, oxygen saturation and
urine dipstick
l laboratory investigations including haemoglobin levels, platelet counts, urine PCR serum and
concentrations of alanine aminotransaminase (ALT), serum aspartate transaminase (AST), serum uric
acid, serum urea and serum creatinine
l treatment measures including administration of antihypertensives and magnesium sulphate.
In addition, we considered estimated fetal weight and liquor volume by ultrasound, uterine artery Doppler,
cardiotocography findings and administration of steroids for prediction of fetal outcomes.
Outcomes
The primary outcome, established using Delphi surveys of experts in the field, was a composite maternal
outcome which included at least one of the following: eclamptic seizures, Glasgow Coma Scale score of
< 13, stroke or reversible ischaemic neurological deficit (RIND), cortical blindness, retinal detachment,
posterior reversible encephalopathy, Bell’s palsy, hepatic dysfunction, liver haematoma or rupture, need for
positive inotrope support, myocardial ischaemia or infarction, at least 50% fraction of inspired oxygen
(FiO2) for > 1 hour, intubation, pulmonary oedema, acute renal insufficiency, dialysis, transfusion of any
blood product, abruptio placentae and postpartum haemorrhage and delivery before 34 weeks’ gestation.
The secondary outcome was a composite fetal outcome, which included one or more of the following:
perinatal or infant mortality, bronchopulmonary dysplasia, necrotising enterocolitis, grade III/IV
intraventricular haemorrhage, cystic periventricular leukomalacia, stage 3–5 retinopathy of prematurity,
hypoxic–ischaemic encephalopathy, stillbirth and admission to the neonatal intensive care unit.
Sample size
We aimed to evaluate 10 candidate predictors in our multivariable model, with at least 10 events per
candidate predictor variable. We assumed that 20% of women with early-onset pre-eclampsia would have
adverse maternal outcomes, with the objective to continue recruitment until 100 events were reached.
Prior to the analysis, we included preterm delivery before 34 weeks as an outcome and we were able to
study over 20 predictors.
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Analysis
Candidate predictors that did not show a normal distribution were log-transformed to improve model fit.
We dealt with missing data by multiple imputation for missing predictor values, except for oxygen
saturation, missing values of which were assumed to be normal. The backward selection procedure was
done to identify predictors for inclusion in the models. Non-linear terms were identified using fractional
polynomials. PREP-L was used to predict risks of any adverse outcome by discharge, and a flexible
parametric model censored at 34 weeks’ gestation was used for PREP-S. The apparent model performance
was evaluated for its ability to discriminate those with and without the outcome (Harrell’s c-statistic for
survival model and the c-statistic for the logistic model) and for calibration defined as the agreement
between observed and predicted risks (by visual inspection of calibration plots).
We internally validated the model by using bootstrapping techniques that quantified the model’s potential
for overfitting, and the amount of optimism in the model’s performance. We then calculated the
optimism-adjusted c-statistic for each model and reduced the predictor effects in the final models by a
uniform shrinkage factor to adjust for optimism.
External validation of the model
We assessed the performance of the models to predict adverse maternal outcomes in the two external
cohorts from the Pre-eclampsia Integrated Estimate of RiSk for mothers (PIERS) and the Pre-Eclampsia TRial
Amsterdam (PETRA) studies. Owing to the missing predictors in the PETRA and PIERS cohorts, it was
necessary to reduce the number of predictor variables in the original PREP models, and the reduced logic
model and survival model (rPREP-L and rPREP-S, respectively) were externally validated.
Results
Between December 2011 and April 2014, 1101 women with suspected or confirmed early-onset
pre-eclampsia were recruited to the study. Of these, the diagnosis was confirmed and maternal outcomes
were known in 946 women. Two-thirds (633/946, 66.9%) experienced at least one adverse maternal
outcome by discharge and 584 (61.7%) experienced an adverse outcome before 34 weeks’ gestation.
Prediction of adverse maternal outcomes
Apparent performance of the PREP-L model
The model included maternal age, gestational age at diagnosis, summary score for medical history
(1 point for pre-existing chronic hypertension, renal disease, diabetes mellitus, autoimmune disease or
previous history of pre-eclampsia), systolic BP, urine PCR, platelet count, serum urea concentration,
baseline treatment with any antihypertensive drug and administration of magnesium sulphate. The
apparent performance of the model showed an optimism-adjusted c-statistic of 0.82 [95% confidence
interval (CI) 0.80 to 0.84] for composite adverse maternal outcomes.
Apparent performance of the PREP-S model
In addition to the predictors included in the PREP-L model, the PREP-S model included exaggerated tendon
reflexes, and concentrations of serum ALT and serum creatinine. The model showed a discrimination
(Harrell’s c-statistic) of 0.75 (95% CI 0.73 to 0.78) for maternal complication after adjusting for optimism.
Performance of the models in external data sets
Data on exaggerated tendon reflexes, serum urea concentration and autoimmune disease in medical
history were not available in the external cohorts. Therefore, we used reduced rPREP-L and rPREP-S models
without these predictors for validation.
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The rPREP-L model showed good discrimination in the PIERS and PETRA data sets, with a c-statistic of
0.81 (95% CI 0.77 to 0.85) and 0.75 (95% CI 0.64 to 0.86), respectively, for maternal complications.
The calibration slope was 0.93 (95% CI 0.72 to 1.10) in the PIERS and 0.90 (95% CI 0.48 to 1.32) in the
PETRA cohort.
The rPREP-S model showed a discrimination of 0.71 (95% CI 0.67 to 0.75) in the PIERS cohort, and a
calibration slope of 0.67 (95% CI 0.56 to 0.79) for adverse maternal outcomes, which suggested large
overprediction of the reduced PREP-S model. We did not validate the PREP-S model in the PETRA data set
because of a lack of information on the timing of outcomes.
Prediction of fetal complications
Multivariable analysis of predictors showed that an increased gestational age at diagnosis of pre-eclampsia
reduced the odds of fetal complications [odds ratio (OR) 0.09, 95% CI 0.01 to 0.61]. A medical history
of pre-existing chronic hypertension, diabetes mellitus, autoimmune disease or renal disease or a history of
pre-eclampsia in previous pregnancies reduced the odds of composite adverse fetal outcomes (OR 0.65,
95% CI 0.44 to 0.98) for one pre-existing medical condition and (OR 0.43, 95% CI 0.25 to 0.77) for
two or more pre-existing medical conditions. The odds of fetal complications were significantly increased
in women with raised urine PCR (OR 1.29, 95% CI 1.11 to 1.50) or serum urea concentration (OR 1.72,
95% CI 1.07 to 2.76), in women being treated with antihypertensive drugs (OR 1.56, 95% CI 1.04 to
2.37) or magnesium sulphate (OR 2.40, 95% CI 1.04 to 5.57), in women in whom uterine artery Doppler
scanning was abnormal (OR 1.94, 95% CI 1.08 to 3.51) and when expected fetal weight was less than the
10th centile, as determined by ultrasound scanning (OR 2.54, 95% CI 1.46 to 4.40).
Conclusions
The PREP-L model provides accurate predictions of the overall severity of the disease, and will be crucial to
plan subsequent care, such as regular follow-ups and admission of high-risk individuals and outpatient
management of those at low risk. The reduced PREP-L model has excellent discrimination and calibration,
even when transported to external validation data sets outside the UK. We expect the full PREP-L model to
have similar, if not better, performance.
The PREP-S model can provide individual risk estimates for adverse maternal outcomes, at various time
points after a diagnosis of early-onset pre-eclampsia to plan management. External validation of the
reduced PREP-S model in a non-UK population shows similar discrimination, but recalibration may be
required to improve the accuracy of predicted risks in populations outside the UK.
Future work recommendations
Further research may examine the impact of implementing the PREP-S and PREP-L models into clinical
practice, in terms of their uptake by clinicians and their impact on patient outcomes.
Trial registration
This trial is registered as ISRCTN40384046.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Introduction
Burden of pre-eclampsia
Pre-eclampsia is a multisystem disorder in pregnancy associated with hypertension and proteinuria.1–3
Hypertension is defined as systolic blood pressure (BP) of ≥ 140 mmHg and diastolic BP of ≥ 90 mmHg on
two occasions between 4 and 6 hours apart.1–3 Proteinuria is defined as ≥ 300 mg of protein in a 24-hour
urine collection period or urine dipstick of 1+ or more in two samples collected 6 hours apart or a spot
urine protein-to-creatinine ratio (PCR) of at least 30 mg/mmol.2–4 Hypertensive diseases in pregnancy
remain one of the leading causes of direct maternal deaths in the UK and account for 20% of all
stillbirths.5 In 1% of pregnant women, pre-eclampsia develops before 34 weeks’ gestation and thus is
called early-onset pre-eclampsia.6,7
Early-onset pre-eclampsia is considered to be a pathophysiologically different disease from late-onset
pre-eclampsia, with considerably increased risk of maternal complications, including a 20-fold higher
maternal mortality.8–10 The only known cure for this condition is delivery of the baby and placenta.
In women with early-onset pre-eclampsia, decisions on the timing of delivery can be difficult, as fetal and
neonatal benefits from prolongation of pregnancy beyond preterm gestation need to be balanced against
the risk of multisystem dysfunction in the mother. Preterm delivery accounts for 65% of neonatal deaths
and 50% of neurological disability in childhood.11 Many of the current practice guidelines do not consider
gestational age at presentation as a criterion for diagnosis, severity or subclassification to stratify risk in
women with pre-eclampsia.2,12
The complexity of the treatment in early-onset pre-eclampsia gives rise to high health-care costs.6,7
Women are often admitted to a tertiary care facility, and one-third experience complications, which may
necessitate admission to an intensive care facility.13 Infants usually need prolonged intensive care treatment
for the management of complications, including lifelong handicaps arising as a result of prematurity. The
additional cost to the NHS of caring for a preterm baby born before 33 weeks’ gestation is £61,509 and
and of a baby born before 28 weeks’ gestation is £94,190.14 Each year, the care of preterm babies costs
the NHS £939M, largely accounted for by neonatal care such as incubation and hospital readmissions.14
Delaying premature births by a week could potentially save £260M a year.14
One of the key recommendations in the last Confidential Enquiries into Maternal and Child Health
(CEMACH) report for policy-makers, service commissioners and providers, and health-care professionals
(now known as the Centre for Maternal and Child Enquiries, CMACE) is the need to adopt an
early-warning system to help in the timely recognition, referral and treatment of women who have or are
developing critical conditions.5 This applies to women with early-onset pre-eclampsia, as early recognition
of women at risk of adverse outcomes will allow timely transfer from a secondary to a tertiary unit to
enable care in a high-dependency unit or neonatal intensive care unit if needed.
Timely prediction of complications in women with early-onset pre-eclampsia involves the use of a
combination of patients’ characteristics, symptoms, physical signs and investigations;15 these ‘tests’ are
performed routinely in all obstetric units, but, in the absence of a structured approach, somewhat
haphazardly. Gestational age is the most important determinant of perinatal outcome with more than
half the chance of intact fetal survival when the gestational age is > 27 weeks and the birthweight is
> 600 g.16 Clinicians are hesitant to advocate expectant management because of uncertainties about the
scale of maternal risk. Development of a prediction model for adverse maternal and fetal outcomes will
help clinicians make appropriate decisions, after discussion with the parents.
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Existing evidence
Evidence on assessment of risk of complications in early-onset pre-eclampsia
At present, it is difficult to identify those mothers with early-onset pre-eclampsia at increased risk of
developing complications, and individual risk estimates for complications at various time points cannot
be provided.9 Current classification systems of pre-eclampsia [Royal College of Obstetricians and
Gynaecologists (RCOG); Australia and New Zealand School of Government (ANZOG); International Society
for the Study of Hypertension in Pregnancy (ISSHP); Community Health Partnerships (CHP); and the
Society of Obstetricians and Gynaecologists in Canada (SOGC)] are based on the severity of the
disease.9,12,17–19 All of them include BP and proteinuria to dichotomise the severity but do not take into
account gestational age to assess severity of pre-eclampsia, with the exception of the SOGC, which
classifies all early-onset pre-eclampsia as severe.19 However, in this subgroup the predictors that influence
maternal and fetal outcomes are not well established.
Our systematic reviews on the accuracy of tests in predicting complications in women with pre-eclampsia
were based on very few, poor-quality primary studies.20–23 They did not take into account the predictive
role of more than one test result on the outcome. Furthermore, there was no separate quantification of
risks, especially in women with early-onset pre-eclampsia.
Prediction models, such as Pre-eclampsia Integrated Estimate of RiSk (PIERS), were developed in women
with any onset pre-eclampsia and not particularly in those with early onset.9 Furthermore, the PIERS model
did not fully account for the treatment paradox, whereby a strong predictor of a common complication
triggers an effective treatment, thereby preventing the occurrence of a certain proportion of adverse
outcomes. In this situation, the predictor that triggered the treatment in the first place will look poorer in
its predictive performance in a simple model.24 Hence, tests such as BP and proteinuria were not identified
to be significant in the PIERS model. This had a negative impact on the face validity of the model, as
traditionally clinicians prioritise these tests and have a very low threshold for intervention when they
are abnormal.
Management of early-onset pre-eclampsia
Currently, the only definitive treatment in pre-eclampsia is delivery. Antenatal corticosteroids are
administered to improve fetal lung maturation whenever preterm delivery is anticipated. As steroids
achieve their optimal effect after 48 hours,25,26 clinicians tend to postpone delivery until this time unless
complications have occurred or are anticipated. Neonatal morbidity from early preterm delivery could be
reduced by stabilising the woman’s condition and, if possible, by delaying delivery. Expectant management
of early-onset pre-eclampsia has been shown to improve perinatal outcomes in randomised trials.27,28
A Cochrane review13 that compared early intervention with expectant management in women with
early-onset severe pre-eclampsia27,28 showed that babies born to mothers in the early intervention group
had more hyaline membrane disease [relative risk (RR) 2.3, 95% confidence interval (CI) 1.4 to 3.8] and
more necrotising enterocolitis (RR 5.50, 95% CI 1.04 to 29.60) and were more likely to be admitted to the
neonatal intensive care unit (RR 1.3, 95% CI 1.1 to 1.6) than those allocated an expectant policy. Infants
in the expectant group were delivered approximately 2 weeks later and were 300 g heavier at birth than
infants in the early intervention group. A recent systematic review of observational studies suggested that
expectant management in carefully selected cases of pre-eclampsia before 34 weeks’ gestation was
associated with few serious maternal complications (median < 5%), similar to interventionist care.9,29
There is consensus that fetal outcome is poor before 24 weeks’ gestation in women with early-onset
pre-eclampsia.27,30,31 However, many centres do not practise expectant management because of the poorly
quantified maternal risk. Our study will establish a predictive rule to allow clinicians to confidently provide
expectant care when risk of complications in early-onset pre-eclampsia is low.
INTRODUCTION
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Objectives
l To develop, and internally validate, a prediction model in women admitted with early-onset pre-eclampsia
from 20+0 weeks to 33+6 weeks’ gestation, for assessment of the risk of adverse maternal outcome by
discharge and at various time points after diagnosis.
l To externally validate and update the model through two external data sets of patients with a
diagnosis of early-onset pre-eclampsia.
l To assess the risk of adverse fetal and neonatal outcomes at birth and at any time until discharge, and
to summarise the unadjusted and adjusted prognostic ability of a set of candidate predictor variables.
DOI: 10.3310/hta21180 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 18
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Thangaratinam et al. under the terms of a commissioning contract issued by the Secretary of State
for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
3

Chapter 2 Development and internal validation
of the prediction model: PREP prospective
observational study
Study methods
The study protocol was developed according to existing recommendations on prognostic research,
model development and validation, and prediction rule development,32–34 and reported in line with the
Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD)
statement.35 The study received ethics approval from the National Research Ethics Service Committee West
Midlands (approval number 11/WM/0248).
Study design and conduct
We undertook a prospective, observational cohort study to develop the prediction model(s). All consecutive
women with suspected or confirmed diagnosis of early-onset pre-eclampsia were approached to take part
in the study. Women were recruited from December 2011 to April 2014 based on a set of prespecified
eligibility criteria and the follow-up of the last participant was completed in July 2014. Potential mothers
were identified and recruited by research midwives and clinicians from the antenatal clinics, wards, day
assessment units and delivery suites. We obtained information routinely collected as part of the antenatal
booking process in the UK such as maternal age, ethnicity, smoking, alcohol intake and substance misuse.
The ethnicity classification was applied using the NHS criteria.36,37
Setting
The multicentre study was conducted in 53 obstetric units within secondary and tertiary care hospitals in
England and Wales.
Participants
Women with suspected or confirmed diagnosis of early-onset pre-eclampsia (before 34 weeks’ gestation)
were recruited to the study. Only women with confirmed early-onset pre-eclampsia were included in the
final models.
Patient and public involvement
The Action on Pre-Eclampsia Charity (APEC) was vital in providing important input. The charity was
involved from the very start with the development and design of the study protocol and will help with the
dissemination of findings from the study. A member of the organisation sat as an independent member of
the study steering committee and contributed to the overall supervision and management of the research
project. They were also involved with the development of study materials, including the informed consent
forms and patient information sheets. The APEC was involved in promoting the study to midwives and
clinicians, attending the study days and meetings.
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Inclusion criteria
The inclusion criteria were gestational age between 20+0 and 33+6 weeks; maternal age of ≥ 16 years; and
a diagnosis of new-onset or superimposed pre-eclampsia. We also included women with a diagnosis of
haemolysis, elevated liver enzymes, low platelets (HELLP) syndrome with no proteinuria or hypertension
and those with one episode of eclamptic seizures but no hypertension or proteinuria.9,38 All women
provided written informed consent and were capable of understanding the information provided. We used
an interpreter if required.
The definitions for diagnosis of pre-eclampsia are provided in Table 1.
Exclusion criteria
Women were excluded if the outcome (including recurrent eclamptic seizures) occurred prior to the tests or
if there was insufficient time for gaining informed consent or if the mother did not comprehend spoken
and written English adequately. A flow chart of study conduct is shown in Figure 1.
TABLE 1 Definitions of the inclusion criteria for women recruited in the Prediction of Risks in Early-onset
Pre-eclampsia (PREP) study
Condition Definition
New-onset pre-eclampsia New-onset hypertension (systolic BP of ≥ 140mmHg or diastolic BP of
≥ 90mmHg on two occasions between 4 and 6 hours apart in women)
after 20 weeks of pregnancy and new-onset proteinuria (≥ 2+ on urine
dipstick or PCR of > 30mg/mmol or 300 mg of protein excretion in
24 hours)39
Suspected pre-eclampsia New-onset hypertension (systolic BP of ≥ 140mmHg or diastolic BP of
≥ 90mmHg on two occasions between 4 and 6 hours apart in women)
after 20 weeks of pregnancy, and 1+ proteinuria on urine dipstick
Superimposed pre-eclampsia
In women with chronic hypertension and no
proteinuria before 20 weeks’ gestation
New-onset proteinuria (as defined previously)
In women with significant proteinuria before
20 weeks’ gestation
Elevated serum alanine aminotransferase concentration (> 70 units per
litre) or worsening hypertension (either two diastolic BP measurements
of at least 110 mmHg 4 hours apart or one diastolic BP measurement
of at least 110 mmHg if the woman had been treated with an
antihypertensive drug), plus one of the following: increasing proteinuria,
persistent severe headaches or epigastric pain
HELLP syndrome HELLP syndrome: presence of haemolysis based on examination of the
peripheral smear, elevated indirect bilirubin levels, or low serum
haptoglobin levels in association with significant elevation in liver
enzymes and a platelet count below 100,000/mm3 after ruling out
other causes of haemolysis and thrombocytopenia
One episode of eclamptic seizures without
hypertension or proteinuria9,38
Other neurological conditions of seizures have been excluded
Reproduced from Thangaratinam S, Allotey J, Marlin N, Dodds J, Cheong-See F, von Dadelszen P, et al. Prediction of
complications in early-onset pre-eclampsia (PREP): development and external multinational validation of prognostic models.
BMC Med 2017;15:68. This article is distributed under the terms of the Creative Commons Attribution 4.0 International
License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any
medium, provided that appropriate credit to the original authors and the source is given.40
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Predictors
Identification of predictors
Our previous Delphi survey of international experts on pre-eclampsia prioritised the tests that were
considered to be clinically important in women with pre-eclampsia.15,41 Additional predictors were identified
from our systematic reviews on the accuracy of tests for complications in pre-eclampsia and other relevant
studies.9 This provided face validity to the choice of tests evaluated in the development of the Prediction
of Risks in Early-onset Pre-eclampsia (PREP) model.
The list of preselected candidate predictor variables evaluated in the PREP study is provided in Box 1 and
the list of predictor variables for fetal complications in the study is shown in Box 2. In addition, we
included management strategies that had the potential to reduce risk of complications to minimise bias
from treatment paradox.24 This included administration of antihypertensive drugs (oral and/or parenteral)
and/or magnesium sulphate if women were on them at the time of diagnosis of early-onset pre-eclampsia,
or if they were commenced within a day of diagnosis. We forced maternal age and gestational age at
diagnosis into the model.
Women with suspected 
and confirmed early-onset 
pre-eclampsia recruited to study
Women with unconfirmed
pre-eclampsia
Adverse maternal
and fetal outcomes
Sensitivity 
analysis
of model 
performance
Baseline characteristics, 
clinical history,
investigations and examinations
Women with confirmed
early-onset pre-eclampsia
Adverse maternal 
and fetal outcomes
PIERS
PETRAa
PREP-L PREP-S
rPREP-L rPREP-S
Population
Predictors
Outcome
External validation
and update of model
Model development
and internal validation
Reduced models prior
to external validation
FIGURE 1 Flow chart of the Prediction of Risks in Early-onset Pre-eclampsia (PREP) study conduct. a, Only reduced
PREP logistic model validated.
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BOX 1 List of candidate predictor variables evaluated in the PREP study
Maternal characteristics
Maternal age at diagnosis (years).
Gestational age at diagnosis (weeks).
Number of fetuses in pregnancy at time of consent (1, 2 or 3).
History
Summary score for medical history – 1 point for each of the following: pre-existing hypertension, renal disease,
diabetes mellitus, autoimmune disease, previous history of pre-eclampsia (0, 1, 2 or more).
Symptoms
Headache and/or visual disturbance (yes/no).
Epigastric pain, nausea and/or vomiting (yes/no).
Chest pain and dyspnoea (yes/no).
Bedside examination and tests
Systolic BP (mmHg, highest measurement over 6 hours).
Diastolic BP (mmHg, highest measurement over 6 hours).
Clonus (yes/no).
Exaggerated tendon reflexes (yes/no).
Abnormal oxygen saturation (< 95% on air) (yes/no).
Urine dipstick (0, 1+, 2+, 3+, 4+ or more).
Laboratory tests
Haemoglobin (g/l).
Platelet count (× 109/l).
ALT concentration (IU/l).
Serum uric acid concentration (µmol/l).
Serum urea concentration (mmol/l).
Serum creatinine concentration (µmol/l).
Urine PCR (mg/mmol).
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Management at baseline
Administration of oral and/or parenteral antihypertensives (ongoing or commenced within 1 day of diagnosis)
(yes/no).
Administration of magnesium sulphate (commenced before or within 1 day of diagnosis) (yes/no).
ALT, alanine aminotransaminase; IU, international unit.
BOX 2 List of predictor variables for fetal complications in the PREP study
Maternal characteristics
Maternal age at diagnosis (years).
Gestational age at diagnosis (weeks).
Number of fetuses in pregnancy at time of consent (1, 2 or 3).
History
Summary score for history, for example 1 point for each of pre-existing hypertension, renal disease, diabetes
mellitus, autoimmune disease, previous history of pre-eclampsia (0, 1, 2 or more).
Symptoms
Headache and/or visual disturbance (yes/no).
Epigastric pain, nausea and/or vomiting (yes/no).
Chest pain and dyspnoea (yes/no).
Bedside examination and tests
Systolic BP (mmHg, highest measurement over 6 hours).
Diastolic BP (mmHg, highest measurement over 6 hours).
Clonus (yes/no).
Exaggerated tendon reflexes (yes/no).
Abnormal oxygen saturation (< 94% on air) (yes/no).
Urine dipstick (0, 1+, 2+, 3+, 4+ or more).
BOX 1 List of candidate predictor variables evaluated in the PREP study (continued)
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Outcome
The primary outcome was composite adverse maternal outcome that included at least one of the
components in Table 2. In addition to maternal complications, prior to the analysis, we added delivery
before 34 weeks’ gestation as an additional component to the composite maternal adverse outcome
to minimise bias caused by treatment paradox. The components of the composite outcome were
developed through Delphic consensus and had previously undergone piloting and validation in the
Canadian cohort of patients in the PIERS (Pre-eclampsia Integrated Estimate of RiSk) study.9 A composite
measure for fetal outcome was also developed by the Delphi consensus9 (Table 3).
Laboratory tests
Haemoglobin (g/l).
Platelet count (× 109/l).
ALT concentration (IU/l).
Serum uric acid concentration (µmol/l).
Serum urea concentration (mmol/l).
Serum creatinine concentration (µmol/l).
Urine PCR in 24 hours (mg/mmol).
Ultrasound and cardiotocography
Uterine artery Doppler at 20–24 weeks’ gestation (normal/abnormal).
CTG findings (normal/abnormal).
Estimated fetal weight by ultrasound (< 10th centile).
Liquor volume (normal/abnormal).
Management at baseline
Administration of oral and/or parenteral antihypertensives (ongoing or commenced within 1 day of diagnosis)
(yes/no).
Administration of magnesium sulphate (commenced within 1 day of diagnosis) (yes/no).
Administration of corticosteroids (commenced within 1 day of diagnosis) (yes/no).
ALT, alanine aminotransaminase; CTG, cardiotocography; IU, international unit.
BOX 2 List of predictor variables for fetal complications in the PREP study (continued)
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TABLE 2 Definitions of the individual components of the maternal composite outcome evaluated in the PREP study
Outcome Definition
Mortality Maternal death attributable to complications of pre-eclampsia
Hepatic dysfunction INR > 1.2 indicative of disseminated intravascular coagulation (DIC) in the
absence of treatment with warfarin. DIC is defined as having both abnormal
bleeding and consumptive coagulopathy (i.e. low platelets, abnormal peripheral
blood film or one or more of the following: increased INR, increased PTT, low
fibrinogen, of increased fibrin degradation products that are outside normal
non-pregnancy ranges)
Hepatic haematoma or rupture Blood collection under the hepatic capsule as confirmed by ultrasound
or laparotomy
Glasgow Coma Scale score of < 13 Based on the Glasgow Coma Scale score system42
Stroke Acute neurological event, with deficits lasting > 48 hours
Cortical blindness Loss of visual acuity in the presence of intact papillary response to light
Reversible ischaemic neurological deficit Cerebral ischaemia lasting > 24 hours but < 48 hours revealed through
clinical examination
Retinal detachment Separation of the inner layers of the retina from the underlying retinal pigment
epithelium (choroid) and is diagnosed by ophthalmological examination
Acute renal insufficiency For women with an underlying history of renal disease defined as a creatinine
concentration of > 200 µM; for patients with no underlying renal disease
defined as a creatinine concentration of > 150 µM
Dialysis Including haemodialysis and peritoneal dialysis
Transfusion of blood products Includes transfusion of any units of blood products: fresh-frozen plasma,
platelets, red blood cells, cryoprecipitate or whole blood
Positive ionotropic support The use of vasopressors to maintain a systolic BP of > 90mmHg or mean arterial
pressure of > 70mmHg
Myocardial ischaemia/infarction ECG changes (ST segment elevation or depression) without enzyme changes
and/or any one of the following:
1. development of new pathological Q waves on serial ECGs. The patient may
or may not remember previous symptoms. Biochemical markers of
myocardial necrosis may have normalised, depending on the length of time
that has passed since the infarct developed
2. pathological findings of an acute, healed or healing myocardial infarction
3. typical rise and gradual fall (troponin) or more rapid rise and fall (creatine
kinase–MB isoenzyme) of biochemical markers of myocardial necrosis with at
least one of the following: ischaemic symptoms
i. development of pathologic Q waves on the ECG;
ii. ECG changes indicative of ischaemia (ST segment elevation or depression)
iii. coronary artery intervention (e.g. coronary angioplasty)
Require > 50% oxygen for > 1 hour Oxygen given at greater than 50% concentration based on local criteria for
> 1 hour
Intubation other than for caesarean
section
Intubation may be by ventilation, electrical impedance tomography or
continuous positive airway pressure
Pulmonary oedema Clinical diagnosis with radiographic confirmation or requirement of diuretic
treatment and SaO2 < 94%
Postpartum haemorrhage Blood loss of > 1 l after delivery
Early preterm delivery Delivery at a gestational age of < 34 weeks
ECG, electrocardiography; INR, international normalised ratio; PTT, partial thromboplastin time; SaO2, saturation of oxygen.
Reproduced from Thangaratinam S, Allotey J, Marlin N, Dodds J, Cheong-See F, von Dadelszen P, et al. Prediction of
complications in early-onset pre-eclampsia (PREP): development and external multinational validation of prognostic models.
BMC Med 2017;15:68. This article is distributed under the terms of the Creative Commons Attribution 4.0 International
License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any
medium, provided that appropriate credit to the original authors and the source is given.40
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When more than one outcome occurred in the same woman, we chose the adverse outcome that occurred
first for the purpose of the survival model. A panel of clinicians with expertise in pre-eclampsia and
prognosis research ranked the maternal outcomes for their importance to clinical care (see Appendix 1).
Sample size
We aimed to examine about 10 candidate predictor variables for inclusion in the model(s). Simulation
studies examining predictor variables for inclusion in logistic regression models suggest that approximately
10 events are necessary for each candidate predictor to avoid overfitting.43–45 Therefore, to examine
10 candidate predictors, we required at least 100 women with adverse maternal outcomes in our cohort.
From our systematic reviews,20–23 20% of women (100 of 500) with early-onset pre-eclampsia were
expected to have adverse maternal outcomes at any time before discharge. Thus, the original target
sample size was 500 women with confirmed pre-eclampsia. As the event rate was lower than predicted,
we revised the sample size to continue recruitment until 100 women had experienced adverse events.
Appendix 2 lists the changes compared to the original protocol submitted to the National Institute for
Health Research Health Technology Assessment programme.
Prior to analysis, after discussion with the steering committee, the study group additionally classified
delivery before 34 weeks’ gestational age as an adverse maternal outcome to avoid treatment paradox
from delivery. The sample size criteria remained the same. With the increased number of outcomes, we
were able to consider about 20 candidate predictors but we maintained at least 10 events per predictor in
the modelling process.
TABLE 3 Definitions of the individual components of the fetal composite outcome evaluated in the PREP study
Outcome Definition
Perinatal or infant mortality Death of a fetus or neonate. Infant mortality is the death of a child < 1 year
of age
Bronchopulmonary dysplasia Oxygen requirement at 36 weeks corrected gestational age unrelated to an
acute respiratory episode
Necrotising enterocolitis including only
Bell’s stage 2 or 3
Evidence of pneumatosis intestinalis on an abdominal radiography and/or
surgical intervention
Grade III/IV intraventricular haemorrhage Bleeding into the brain’s ventricular system, where ventricles are enlarged by
the accumulated blood or bleeding extends into the brain tissue around the
ventricles
Cystic periventricular leukomalacia Softening and necrosis in the hemispheric white matter in newborns that may
result from impaired perfusion at the interface between ventriculopetal and
ventriculofugal arteries
Stages 3–5 retinopathy of prematurity Abnormal blood vessel development in the retina of the eye, where blood vessel
growth is severely abnormal, where there is a partially or totally detached retina
Hypoxic–ischaemic encephalopathy Apgar score of ≤ 5 at 10 minutes and/or pH 7.00 in first 60 minutes of life
and/or base deficit ≥ –16 in first 60 minutes of life associated with abnormal
consciousness level (lethargy, stupor or coma) and seizures and/or poor/weak
suck and/or hypotonia and/or abnormal reflexes
Reproduced from Thangaratinam S, Allotey J, Marlin N, Dodds J, Cheong-See F, von Dadelszen P, et al. Prediction of
complications in early-onset pre-eclampsia (PREP): development and external multinational validation of prognostic models.
BMC Med 2017;15:68. This article is distributed under the terms of the Creative Commons Attribution 4.0 International
License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any
medium, provided that appropriate credit to the original authors and the source is given.40
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Data sets for external validation: PIERS and PETRA studies
The PREP model was externally validated in two external independent data sets from the PIERS9 and the
Pre-Eclampsia TRial Amsterdam (PETRA)46 studies.
PIERS study
The aim of this prospective observational study was to develop a prediction model for adverse maternal
outcomes in women with pre-eclampsia of any onset (both early and late).9 Two thousand and twenty-three
women were recruited from tertiary perinatal units in Canada, New Zealand, the UK and Australia between
1 September 2003 and 31 January 2010. Women were included if they were admitted with pre-eclampsia or
had developed pre-eclampsia after admission. Women were excluded if they were admitted in spontaneous
labour or had achieved any component of the maternal outcome before either fulfilling eligibility criteria or
collection of predictor data. The primary outcome was a composite maternal outcome. The combined
adverse maternal outcome included one or more of the following: maternal mortality or a serious central
nervous system, cardiorespiratory, hepatic, renal, or haematological morbidity. We used the anonymised
data set of women with early-onset pre-eclampsia in the PIERS study to validate the PREP model.
PETRA study
The PETRA study was a randomised controlled trial evaluating the effectiveness of plasma expansion in
expectant management of early-onset hypertensive disease in pregnancy, including pre-eclampsia.46
Women were recruited from two university hospitals, the Department of Obstetrics at the Academic
Medical Centre and the Vrije University Medical Centre Amsterdam, between April 2000 and May 2003.
Patients across the spectrum of severe hypertensive disorders of pregnancy were included in the trial.
Patients were excluded if severe fetal distress or lethal fetal congenital abnormalities were diagnosed, if
language difficulties prevented informed consent-taking, or if plasma volume expansion had already been
given. A total of 216 women were randomised, 111 to plasma volume expansion and 105 to no plasma
volume expansion (the control group). The primary outcomes were neonatal neurological development at
term age (Prechtl score),47 perinatal death, neonatal morbidity and maternal morbidity. The intervention
showed no significant difference in outcomes between the two groups. Data from the entire study cohort
were used in the external validation of the PREP model.
Analysis plan development
We convened a panel of 24 experts in the field of pre-eclampsia and prognostic research, to explore the
challenges and potential solutions in the development of a prediction model. The panel focused its
discussion on methods to reduce the risk of bias in the PREP models as a result of treatment paradox.24
After consideration of various methods, it was decided to include effective treatments such as
antihypertensive drugs and magnesium sulphate as predictors to avoid bias. The appropriateness
of the population, predictors and outcomes was discussed. The methodological issues pertinent to the
analysis, such as the choice of model (logistic or survival), were considered and the panel suggested
the development of both models.
Statistical analysis
We used a transparent process with appropriate prognostic research methodology for our analysis,
and reported using TRIPOD recommendations.35 We developed and externally validated two models: a
logistic model (PREP-L) for overall risk of any adverse outcome by discharge, and a survival model (PREP-S)
to assess the risk of adverse outcomes at various time points from diagnosis of pre-eclampsia until
34 weeks’ gestation.
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Data preparation
We produced descriptive tables of baseline characteristics, candidate predictors and outcomes. Candidate
predictors were checked for normality and log-transformed if applicable. We avoided dichotomisation of
continuous variables to avoid loss of information. Only pulse oximetry findings were dichotomised because
of the very small variations in values.
Methods for handling missing values
During model development, to deal with missing predictor values in some patients, multiple imputation
was performed (under a missing at random assumption) using the user-written ICE package in Stata
version 12 (StataCorp LP, College Station, TX, USA) with five imputations. We combined the estimates
across imputed data sets using Rubin’s rules to produce final parameter estimates for the model.48
All missing values of candidate predictor variables were multiply imputed except for pulse oximetry and
previous occurrence of pre-eclampsia. Previous occurrence of pre-eclampsia was always classed as a ‘no’ in
nulliparous women. Pulse oximetry was assumed normal if missing. The imputation of missing data was
performed on the complete data set of all participants with suspected or confirmed pre-eclampsia. This
was to allow as much information as possible into the imputation procedure. Apart from the eight women
lost to follow-up after baseline, no outcome data were missing; therefore, no outcomes were imputed.
Selection of predictor variables
For both primary models, all 22 variables listed in Box 1 were considered to be candidate predictor
variables for inclusion in our maternal model. A backwards selection procedure was used to decide which
of the candidate predictor variables should be included in the final prediction model (with a p-value of
< 0.15 conservatively taken to warrant inclusion and prevent omission of important predictors). Gestational
age and maternal age at diagnosis were forced into the model, to ensure clinical acceptability of the final
model. For categorical variables, such as medical history and urine dipstick, we used the lowest p-value
of any category (relative to the reference category) to indicate inclusion or exclusion.
Continuous variables were initially selected based on an assumed linear trend. After inclusion, non-linear
trends were also evaluated using fractional polynomials (FPs), with a p-value of < 0.01 (for the change in
model fit) used to justify the inclusion of non-linear trends. Any continuous variables that were originally
dropped were double-checked for whether or not non-linear trends would alternatively suggest
their inclusion.
Model development for adverse maternal outcomes
We applied the modelling process to women with confirmed diagnosis of early-onset pre-eclampsia and
had complete outcome data (Figure 2).
Definition of survival time
For survival analysis, the end of follow-up was defined as the time of occurrence of the first adverse outcome
or end of 34 weeks’ gestation, whichever occurred first. A woman was considered to be at risk from the
time of diagnosis of early-onset pre-eclampsia and the failure event was defined as maternal adverse
outcome occurring before 34 weeks’ gestation. The survival data information was described in the original
data set and copied into all five imputed data sets. The survival information was independent of the multiple
imputation, as no outcome was imputed and the time of diagnosis data were available for all women.
Survival model: flexible parametric model
A flexible parametric survival model was used via the Royston–Parmar approach,49–51 with the cumulative
baseline hazard scale modelled using restricted cubic splines (implemented as the stpm2 package in Stata12).
We chose this approach over a Cox regression as it allowed us to explicitly model the baseline hazard rate
allowing non-linear functions via cubic splines, which are very flexible and relatively simple to work with.
Simpler parametric models may not be flexible enough to adequately represent the hazard function.
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Splines are flexible mathematical functions defined by piecewise polynomials, with some constraints to
ensure that the overall curve is smooth. The points at which the polynomials join are called knots. Royston
and Lambert50 explain that the stpm2 uses restricted cubic splines which force the function to be linear
before the first knot and after the final knot. Let s(x) be the restricted cubic spline function. Defining m
interior knots, k1, . . ., km, and also two boundary knots, kmin and kmaxs(x), can be written as a function of
parameters γ and some newly created variables z1, . . ., zm+ 1 giving:
s(x)=γ0+γ1z1 + γ2z2+⋯+ γm+1zm+1. (1)
The derived variables zj (also known as the basis functions) can be calculated as follows:
z1=x
z j= (x−k j)3−λ j(x−kmin )3− (1−λ j)(x−kmax )3,
(2)
where j = 2, . . ., m + 1,
Eligible women 
(n = 1203)
Eligible but not recruited
(n = 102)
• Refused consent, n = 36
• Missed for screening, n = 66
Total recruited
 (n = 1101)
• No baseline data, n = 5
• Suspected but not confirmed
   pre-eclampsia, n = 142
Number with confirmed
pre-eclampsia
 (n = 954)
Number available for 
secondary (fetal) analysis 
(n = 945)
Lost to follow-up 
(n = 8)
Complete cases of confirmed 
pre-eclampsia for primary 
(maternal) analysis 
(n = 946)
Lost to follow-up 
(n = 1)
FIGURE 2 Flow of women recruited in the PREP study for development of the prediction model(s) for adverse
maternal and fetal outcomes.
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λ j=
kmax −k j
kmax −kmin
. (3)
When choosing the location of the knots for the restricted cubic splines, it is useful to have some sensible
default locations. In stpm2, the default knot locations are at the centiles of the distribution of uncensored
log-event times.
Survival null model
We identified the number of knots to go into the model by fitting the null model with an increasing
number of knots. The number of knots was chosen based on the lowest Akaike information criterion/
Bayesian information criterion (AIC/BIC) and visual inspection of the change in fitted shape, with
preference for simplicity (i.e. fewer knots) to avoid overfitting. AIC and BIC are measurements of model fit.
Univariable model, full model and variable selection process
Univariable analyses were performed for both models on all 22 candidate predictors in their linear
(log-transformed, if applicable) form. These were fitted in each imputed data set and combined using
Rubin’s rules.48 Univariable analyses were performed only to summarise the unadjusted associations in the
data, and were not used to inform the selection of predictors in the final multivariable models. Where
applicable and computationally possible, all analyses were performed with the imputed data sets and the
results were combined appropriately. A backwards selection procedure was applied to both full models
as previously described. Maternal age and gestational age at diagnosis were forced into the model.
The model was refitted after dropping each individual predictor.
Non-linear terms
We identified the non-linear terms using the multivariable FP (MFP) procedure in Stata, which selects the
MFP model that best predicts the outcome variable. The MFP procedure allows the selection of non-linear
terms for continuous variables and the procedure was applied to each of the five multiply imputed data
sets separately, and the pattern that was identified by the majority of multiply imputed data sets was used
(on consensus between the lead statisticians). In order to avoid overfitting, only non-linear terms that
improved the model fit at a minimum significance level of 1% (test of deviance) were considered. The final
models were refitted by including the FP terms and checked for dropping further predictors at a p-value
of < 0.150. Such variables were dropped only if their exclusion did not change the FP terms already
identified in the previous step. This step was performed only once and was not repeated if additional
predictors had p-values of ≥ 0.150.
Sensitivity analyses
Logistic and survival model
We included treatment with any antihypertensive drug (oral and/or parenteral) within 1 day of diagnosis in
the final models. As parenteral antihypertensive drugs are usually commenced in severe pre-eclampsia to
prevent complications, the predictive values could be different for oral and parenteral antihypertensive
drugs. A sensitivity analysis was conducted by including oral and parenteral antihypertensive drugs
separately in the final models to check if model fitting is improved.
Survival model only
The full survival model needed to be fitted in each of the imputed data sets and the results combined
using Rubin’s rules. This procedure is not officially supported for use with the stpm2 command in Stata,
although it does perform the estimation if forced. In order to confirm accuracy of the results, we fitted a
Cox regression for the same model. The stcox command is supported for the combination of estimations
using Rubin’s rules. We also checked the final survival model for time-dependent effects.
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Apparent performance
The apparent performance of the fitted models was examined by calculating discrimination performance
using the c-statistic for the logistic model and Harrell’s c-statistic for the survival model,52 with a 95%
confidence interval (CI), in the same data used to generate the model. A c-statistic close to 1 indicates
excellent discrimination and 0.5 indicates no discrimination beyond chance. The calibration performance
(fit of observed to expected risk across all individuals) was examined by checking that the calibration slope
was 1. As the model was developed using the same data, we expected the calibration to show perfect
agreement on average across the individuals.
Internal validation
To evaluate the potential for overfitting of our developed models, we used non-parametric bootstrapping.
The variable selection procedure was repeated in 100 bootstrap data sets from each of the five multiple
imputation data sets (thereby giving a total of 500 data sets). This led to a new final model being
produced in each of the bootstrap samples. The performance of the models (in terms of c-statistic and
calibration slope) in the bootstrap sample itself represents an estimation of the apparent performance,
and their performance in the original sample represents test performance. The difference between these
performances is an estimate of the optimism in the apparent performance. This difference was averaged
to obtain a single estimate of optimism for the c-statistic and the calibration slope. This optimism was
then subtracted from the original apparent performance statistics to produce optimism-adjusted
performance statistics.
Production of the final models
The coefficients in the final models were adjusted for optimism. The optimism-adjusted calibration slope
was taken as the uniform shrinkage factor, and the original predictor effects (beta coefficients) were
multiplied by this value. Following this, the intercept (for the logistic model) or baseline hazard (for the
survival model) were re-estimated to ensure that the overall calibration of the final model predictions to
the observed data were maintained, that is, to ensure that calibration-in-the-large was zero. For the
survival model, only the intercept term was modified in the baseline hazard function (i.e. the shape of
the original baseline hazard was maintained). For sensitivity analysis, we applied these optimism-adjusted
models to women with an unconfirmed diagnosis of pre-eclampsia.
After developing and validating the prediction model based on the final set of (close to) 20 predictors,
we additionally investigated whether or not any of the candidate predictors we excluded would actually
significantly improve the accuracy of the model; however, this was clearly noted as secondary analyses.
The models were available as Microsoft Excel® (Microsoft Corporation, Redmond, WA, USA) files (see
Appendices 3 and 4) to allow clinicians to input the findings of their patients, and obtain estimates of
overall risk of adverse outcomes (PREP-L) and risks at daily intervals after diagnosis (PREP-S).
External validation
The final models were externally validated using the PIERS and PETRA data. We compared the availability
of predictors, missing values and the outcome components in the external data sets with the PREP data.
If there were any missing predictors in the external cohorts, we planned to re-estimate a reduced version
form of our model (using exactly the same process as above) using only those predictors that were
available in the external data sets.
If predictors were centred in the PREP model, then predictors in the external data were centred by the
same value. The reduced PREP models were used to estimate predicted risks (or risk scores) for women in
the PIERS or PETRA population. To produce calibration plots, the risks were grouped into tenths (defined
by centiles) of predicted risk in the PREP-L model and into four risk groups for the PREP-S model. As the
predictions were not compatible with the Stata 12.1 facilities for combining results using Rubin’s rules, we
calculated the fitted values or predictions of risk within each imputed data set and then averaged them.
DOI: 10.3310/hta21180 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 18
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Thangaratinam et al. under the terms of a commissioning contract issued by the Secretary of State
for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
17
Secondary analysis of fetal outcomes
The analysis of fetal outcomes by discharge was done in the same way as for the logistic model described
above, although non-linear terms were not considered. Analysis was performed on the level of the mother/
pregnancy rather than on the fetal level. In multiple pregnancies with multiple sets of predictors and
outcomes, we used the worst predictor and considered any outcome regardless of whether an outcome
occurred in one of the babies or in both. A variable selection process on the full list of maternal and fetal
candidate predictors provided the final fetal model. No adjustment for optimism, external validation or
sensitivity analyses was performed for the fetal model.
All the above analyses were carried out using Stata version 12.0. Definitions of key terms are provided
in Table 4.
TABLE 4 Definitions of key model performance terms
Terms Definitions
Calibration Calibration indicates the ability of the model to correctly estimate the absolute risks
and was examined using calibration plots
Reproducibility (internal validation) The process of determining internal validity. Internal validation assesses validity for the
setting from which the development data originated
Generalisability/transportability
(external validation)
The process of determining external validity of the prediction model to populations
that are plausibly related
Discrimination Discrimination describes the ability of the model to correctly distinguish those who
will have an adverse outcome from those who will not
Calibration plot In a calibration plot the predictive risk plotted against the observed incidence of
the outcome. Ideally the predicted risk equals the observed incidence throughout the
entire risk spectrum and the calibration plot follows the 45° line
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Chapter 3 Maternal characteristics, predictors and
outcomes in women with early-onset pre-eclampsia
Flow of participants in the study
Between December 2011 and April 2014, we screened 3302 pregnant women from 53 maternity units
for inclusion in the PREP study. Of these, 2099 did not meet the inclusion criteria: 882 did not have
raised proteinuria, 650 did not have raised BP readings, 457 were classed as other, 53 had underlying
comorbidities, 36 were participating in a clinical trial of an investigational medicinal product and 21 did
not understand English and an interpreter could not be used at the time of recruitment. Of the 1203
eligible women, 1101 were recruited to the study with a suspected or confirmed diagnosis of early-onset
pre-eclampsia. Of those recruited, 954 women had confirmed pre-eclampsia, 142 women had a suspected
diagnosis of pre-eclampsia that was not subsequently confirmed, baseline information data were not
available in five participants and nine were lost to follow-up. The final maternal prediction models included
data from 946 women and the fetal prediction model included data from 945 pregnancies (see Figure 2).
Baseline characteristics of women included in the PREP study
Table 5 shows the women recruited into the study according to the various inclusion criteria. Over 90%
(866/954) of all participants had a diagnosis of new-onset pre-eclampsia, 75 women (75/954, 7.9%) had
superimposed pre-eclampsia, 10 (10/954, 1.0%) had HELLP syndrome and three women (3/954, 0.3%)
had a single episode of eclamptic seizure in the absence of raised BP or proteinuria.
The mean age of participants was 30.2 years [standard deviation (SD) 6.1 years] (Table 6). Two-thirds
of women identified themselves as European (631/950, 66%), one-fifth as South or South-East Asian
(18%, 172/950) and about one-tenth (81/950, 9%) as African. Around 3% of all women were from the
Caribbean (31/950), 1% from the Far East (8/950) and 1% from the Middle East (6/950). Ninety-one per
cent (866/954) of all pregnancies were singletons, while twins and triplets accounted for 9% (83/954) and
1% (5/954) of pregnancies, respectively. More than half of all women were nulliparous (551/954, 58%).
Recurrent miscarriage (three or more) had occurred in 42 women (4.4%). About one-tenth (87/943, 9%)
of women reported smoking in pregnancy at booking appointment and alcohol intake in pregnancy was
reported by 5% (47/937) of all participants.
TABLE 5 Women recruited to the PREP study according to the various inclusion criteria
Inclusion criteria Women, n (%)
New-onset pre-eclampsia 866 (91.0)
Superimposed pre-eclampsia 75 (7.9)
HELLP syndrome 10 (1.0)
Eclamptic seizures 3 (0.3)
Total 954
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Predictor characteristics in women with early-onset
pre-eclampsia
The values of the various candidate predictors of women in the PREP study are shown in Table 7.
The mean gestational age at which the diagnosis of early-onset pre-eclampsia was made was 30.5 weeks
(SD 2.9 weeks) and there were no missing values for gestational age at diagnosis.
Clinical history
One-quarter (251/953, 26%) of all women for whom data were available had at least one of the following
risk factors: previous history of pre-eclampsia (169/396, 43%), chronic hypertension (139/944, 15%),
diabetes mellitus (109/948, 11%), renal disease (30/944, 3%) and autoimmune disease (18/922, 2%).
One-tenth (101/953, 11%) had two or more risk factors.
TABLE 6 Descriptive characteristics of women recruited in the PREP study
Maternal characteristics
Women with early-onset pre-eclampsia (n= 954)
Mean (SD) or n (%)
Maternal age (years), mean (SD) 30.2 (6.1)
Alcohol intake 47 (5%)
Currently smoking 87 (9%)
Drug use 4 (0.4%)
Mother’s ethnic group
Europe 631 (66%)
Africa 81 (9%)
South and South East Asia 172 (18%)
Far East 8 (1%)
Middle East 6 (1%)
Caribbean 31 (3%)
Other 21 (2%)
Parity
0 551 (58%)
1 207 (22%)
2 109 (11%)
3 55 (6%)
4 20 (2%)
5–9 12 (1%)
Total number of miscarriages
0 607 (64%)
1 225 (24%)
2 72 (8%)
> 3 42 (4%)
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TABLE 7 Details of candidate predictors of women in the PREP study and the proportion with missing values
Candidate predictor
Women with early-onset
pre-eclampsia (N= 954)
Women with missing data, n (%)Mean (SD) or n (%)
Maternal characteristics
Maternal age (years), mean (SD) 30.2 (6.1) 2 (0.2)
Gestational age at diagnosis (weeks), mean (SD) 30.5 (2.9) –
Number of fetuses in pregnancya
Singleton 866 (91%) –
Twins 83 (9%) –
Triplets 5 (1%) –
History
Summary score for medical historyb 1 (0.1)
0 601 (63%) –
1 251 (26%) –
≥ 2 101 (11%) –
Chronic hypertension 139 (15%) 10 (1.0)
Renal disease 30 (3%) 10 (1.0)
Previous history of pre-eclampsia 169 (43%) 558c
Autoimmune disease 18 (2%) 32 (3.4)
Pre-existing DM 109 (11%) 6 (0.6)
Type I DM 56 (51%) –
Type II DM 16 (15%) –
Gestational DM 37 (34%) –
Symptoms
Headache and/or visual disturbance 382 (40%) 28 (2.9)
Headache generalised 293 (31%) 36 (3.8)
Headache localised 121 (13%) 92 (9.6)
Visual disturbance 139 (15%) 56 (5.9)
Epigastric pain, nausea and/or vomiting 202 (22%) 47 (4.9)
Epigastric pain 131 (14%) 68 (7.1)
Nausea 111 (12%) 130 (13.6)
Vomiting 54 (6%) 120 (12.6)
Chest pain and/or breathlessness 60 (6%) 126 (13.2)
Chest pain 30 (3%) 164 (17.2)
Breathlessness 38 (4%) 162 (17.0)
continued
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TABLE 7 Details of candidate predictors of women in the PREP study and the proportion with missing values
(continued )
Candidate predictor
Women with early-onset
pre-eclampsia (N= 954)
Women with missing data, n (%)Mean (SD) or n (%)
Bedside examination and tests
Systolic BP (mmHg), mean (SD) 159 (19) 5 (0.5)
Diastolic BP (mmHg), mean (SD) 99 (12) 5 (0.5)
Clonus 95 (10%) 403 (42.2)
Exaggerated tendon reflexes 147 (15%) 353 (37.0)
Oxygen saturation by pulse oximetry (%), mean (SD) 98 (2) 521 (54.6)
Oxygen saturation abnormal (< 94%) 4 (≥ 1%) 521 (54.6)
Urine dipstick
None/trace 39 (4%) –
1+ 170 (18%) –
2+ 314 (33%) 19 (2.0)
3+ 306 (32%) –
≥ 4 106 (11%) –
Laboratory tests
Haemoglobin (g/l), mean (SD) 11.9 (1.3) 37 (3.9)
Platelet count (× 109/l), mean (SD) 226 (78) 41 (4.3)
ALT concentration (U/l), mean (SD) 31.0 (71.0) 75 (7.9)
Serum uric acid concentration (µmol/l), mean (SD) 0.6 (2.7) 165 (17.3)
Serum urea concentration (mmol/l), mean (SD) 4.6 (4.4) 70 (7.3)
Serum creatinine concentration (µmol/l), mean (SD) 61.0 (17.8) 38 (4.0)
Urine PCR 24 hour (mg/mmol), mean (SD) 273 (492) 109 (11.4)
Treatment provided
Any antihypertensive therapyd 753 (79%) 6 (0.6)
Oral antihypertensive therapy 734 (77%) 6 (0.6)
Parenteral antihypertensive therapy 111 (12%) 6 (0.6)
Intravenous magnesium sulphatee 144 (15%) 6 (0.6)
ALT, alanine aminotransaminase; DM, diabetes mellitus.
a Values represent the number of pregnancies.
b Each contributes to 1 point scored for medical history.
c All missing values are nulliparous women. Previous occurrence of pre-eclampsia is not applicable.
d Ongoing at diagnosis or introduced within 1 day of diagnosis.
e Administered any time before diagnosis or within 24 hours of diagnosis.
Reproduced from Thangaratinam S, Allotey J, Marlin N, Dodds J, Cheong-See F, von Dadelszen P, et al. Prediction of
complications in early-onset pre-eclampsia (PREP): development and external multinational validation of prognostic models.
BMC Med 2017;15:68. This article is distributed under the terms of the Creative Commons Attribution 4.0 International
License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any
medium, provided that appropriate credit to the original authors and the source is given.40
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Symptoms
Symptoms such as headache and/or visual disturbances were experienced by 41% (382/926) of women,
epigastric pain and/or vomiting by 22% (202/907) and chest pain and/or dyspnoea by 7% (60/828).
Bedside examination and tests
The mean systolic and diastolic BP at the time of diagnosis of early-onset pre-eclampsia was 159 mmHg
(SD 19 mmHg) and 99 mmHg (SD 12 mmHg), respectively. Around two-thirds of women had demonstrable
clonus (551/954, 58%) and exaggerated tendon reflexes (601/954, 63%). The oxygen saturation levels
were ≤ 94% in only 1% (4/433) of women, and more than half of the women did not have documented
results (521/954, 55%). There were no missing values for BP or proteinuria.
Laboratory tests
Serum alanine aminotransaminase (ALT) was measured more often than aspartate transaminase (AST)
(in 93% of women vs. 30%); consequently, ALT was used in the analysis. Less than one-tenth of values
were missing for haemoglobin level, platelet count and concentrations of serum urea and serum creatinine
concentration. Furthermore, < 20% of values were missing for serum uric acid concentration.
Treatment provided
More than three-quarters (753/948, 79%) of women were previously on antihypertensive drugs or were
started on them within the first 24 hours of diagnosis of pre-eclampsia. Three-quarters of women
(734/948, 77%) were on oral antihypertensive therapy and 12% (111/948) were receiving parenteral
antihypertensive therapy. Fifteen per cent (144/948) of women started magnesium sulphate treatment to
prevent or treat eclamptic seizures in the first 24 hours after diagnosis.
Additional fetal predictors
For the analysis of fetal outcomes, five additional predictors were included, as shown in Table 8. Around
one-quarter (91/342, 27%) of women had an abnormal uterine artery Doppler at 20–24 weeks’ gestation.
Only 6% of women had abnormal liquor volume (57/898) and 5% had abnormal cardiotocography (CTG)
findings (46/713). Over 40% (291/717) of pregnancies had an estimated fetal weight < 10th centile.
More than half (430/783, 55%) of the women received treatment with corticosteroids at baseline.
Maternal and fetal adverse outcomes in women with
early-onset pre-eclampsia
Outcome data were available for 99% (946/954) of all participants in the PREP study. The rates of individual
components of the composite adverse maternal and fetal outcomes are provided in Tables 9 and 10,
respectively.
TABLE 8 Details of fetal predictors in the PREP study and the proportion with missing values
Additional fetal predictors
Women with early-onset
pre-eclampsia (n= 954),
mean (SD) or n (%)
Women with
missing data, n (%)
Abnormal uterine artery Doppler 91 (10%) 612 (64)
Abnormal liquor volume 57 (6%) 56 (6)
Abnormal CTG findings 46 (5%) 241 (25)
Estimated fetal weight < 10th centile 291 (31%) 237 (25)
Baseline treatment: steroids 430 (45%) 171 (18)
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TABLE 9 Rates of individual maternal complications in women with early-onset pre-eclampsia in the PREP study
Adverse maternal outcome Women with complications (N= 946), n (%)
Maternal death –
Neurological
Eclamptic seizures 12 (1.3)
Glasgow Coma Scale score of < 13 3 (0.3)
Stroke or RIND –
Cortical blindness –
Retinal detachment –
Posterior reversible encephalopathy 2 (0.2)
Bell’s palsy –
Hepatic
Hepatic dysfunction 12 (1.3)
Subcapsular haematoma –
Hepatic capsule rupture –
Cardiorespiratory
Need for positive inotrope support 1 (0.1)
Myocardial ischaemia or infarction –
At least 50% FiO2 for > 1 hour 7 (0.7)
Intubation 9 (1.0)
Pulmonary oedema 6 (0.6)
Renal
Acute renal insufficiency 5 (0.5)
Dialysis 5 (0.5)
Haematological
Transfusion 51 (5.4)
Abruptions 25 (2.6)
Postpartum haemorrhage 74 (7.8)
Preterm delivery
Delivery at < 34 weeks’ gestational age 580 (61.3)
At least one of the above occurred by discharge 633 (66.9)
At least one occurred before 34 weeks’ gestational age 584 (61.7)
FiO2, fraction of inspired oxygen; RIND, reversible ischaemic neurological deficit.
Reproduced from Thangaratinam S, Allotey J, Marlin N, Dodds J, Cheong-See F, von Dadelszen P, et al. Prediction of
complications in early-onset pre-eclampsia (PREP): development and external multinational validation of prognostic models.
BMC Med 2017;15:68. This article is distributed under the terms of the Creative Commons Attribution 4.0 International
License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any
medium, provided that appropriate credit to the original authors and the source is given.40
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Overall, 66.9% (633/946) of all women with early-onset pre-eclampsia experienced at least one adverse
maternal outcome and 74.3% (702/945) had at least one adverse fetal outcome. The most frequently
reported outcome was preterm delivery before 34 weeks’ gestation, occurring in 61.3% (580/946) of
women. The second most common outcome was postpartum haemorrhage (7.8%, 74/946), followed by
transfusion of any blood products (5.4%, 51/946) and abruptio placentae (2.6%, 25/946). The least
reported maternal complications were need for positive inotrope support (0.1%, 1/946), posterior
reversible encephalopathy (0.2%, 2/946) and a Glasgow Coma Scale score of < 13 (0.3%, 3/946). When
preterm delivery was excluded as a component of the composite outcome, 15.5% of all women (147/946)
had at least one adverse maternal outcome.
TABLE 10 Rates of individual fetal and neonatal complications in the PREP study
Adverse fetal outcome Pregnancies with complications (N= 945a), n (%)
Neonatal death 23 (2.4)
Bronchopulmonary dysplasia 41 (4.3)
Necrotising enterocolitis 34 (3.6)
Grade III/IV intraventricular haemorrhage 11 (1.2)
Cystic periventricular leukomalacia 5 (0.5)
Stage 3–5 retinopathy 7 (0.7)
Hypoxic ischaemic encephalopathy 2 (0.2)
Stillbirth 16 (1.7)
Admission to NICU at any time 681 (72.1)
At least one of the above occurred by discharge 702 (74.3)
NICU, neonatal intensive care unit.
a Excludes one participant whose fetal outcome data were lost to follow-up.
Reproduced from Thangaratinam S, Allotey J, Marlin N, Dodds J, Cheong-See F, von Dadelszen P, et al. Prediction of
complications in early-onset pre-eclampsia (PREP): development and external multinational validation of prognostic models.
BMC Med 2017;15:68. This article is distributed under the terms of the Creative Commons Attribution 4.0 International
License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any
medium, provided that appropriate credit to the original authors and the source is given.40
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Chapter 4 Prediction of overall risk of adverse
maternal outcome by discharge in women with
early-onset pre-eclampsia: PREP-L model
O f the 946 women for whom outcome data were available, 633 (67%) experienced at least oneadverse maternal outcome at any time from diagnosis to discharge. The number of women who had
experienced an adverse outcome was 228 (24%) at 48 hours, 410 (43%) at 1 week and 624 (66%) at
30 days after diagnosis.
Modelling continuous predictors
Maternal age, systolic and diastolic BPs, haemoglobin level and platelet count were normally distributed,
and hence we did not apply any transformation. Concentrations of ALT, AST, serum uric acid, serum urea
and serum creatinine and the PCR were strongly right skewed, and we log-transformed these values.
As gestational age at diagnosis was an inclusion criterion and limited to 34 weeks, a log transformation
was applied to decrease the range. We were not able to fully evaluate serum uric acid concentration as a
predictor because of data coding issues in this variable at the time of model development. Subsequent to
model development being completed, and after the data coding issues were resolved for this variable,
we calculated how the c-statistic changed after adding log-transformed serum uric acid concentration to
the final models to assess whether or not this variable improved model performance (see Apparent
performance and internal validation of the PREP-L model).
Development of PREP-L model: predictor selection
Table 11 shows the univariable and multivariable analysis for association of predictors and adverse
maternal outcomes. The models were fitted in each of the imputed data sets and the results combined
using Rubin’s rules. In the univariable analysis, lower gestational age at diagnosis, symptoms of epigastric
pain and/or nausea and vomiting, clonus, exaggerated tendon reflexes, raised systolic and diastolic
BPs, urine dipstick-detectable proteinuria, high levels of haemoglobin, low platelet counts, raised
concentrations of ALT, serum urea, serum uric acid and creatinine, increased urine PCR, management
with antihypertensives and use of magnesium sulphate were significantly associated with adverse maternal
outcomes (p < 0.05). Relevant medical history of one or more conditions such as chronic hypertension,
diabetes mellitus, renal disease, autoimmune disease and a history of pre-eclampsia in previous pregnancy
were associated with a reduced risk of complications.
Predictor variables were dropped stepwise based on the largest p-value. The final list of predictors for
the logistic model were maternal age, log-transformed gestational age at diagnosis, summary score
for medical history, systolic BP, platelet count, log-transformed serum urea concentration, log-transformed
PCR, baseline treatment with any antihypertensive and baseline treatment with magnesium sulphate.
Transformation of predictors for the final PREP-L model
We considered the following continuous variables for non-linear terms: maternal age, log-transformed
gestational age at diagnosis, systolic BP, platelet count, log-transformed serum urea concentration and
log-transformed PCR.
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Appendix 5 shows the FP terms identified within each multiply imputed data set and the p-value for the
test of deviance comparing the FP model with the model including linear terms only. Non-linear terms
were identified as significant at the 1% level for log-transformed gestational age at diagnosis and serum
urea concentration.
Final PREP-L model before adjusting for optimism
Table 12 shows the final logistic model after multiple imputation, including FP terms, and prior to
adjustment for optimism.
The final PREP-L model identified that maternal age, early gestational age at diagnosis of pre-eclampsia,
raised systolic BP, high urine PCR, high serum urea concentration, low platelet counts, need for treatment
with antihypertensive drugs and administration of magnesium sulphate were associated with increased risk
of adverse maternal outcomes. A positive medical history for pre-existing medical conditions or a previous
history of pre-eclampsia was associated with a reduced risk of complications.
Apparent performance and internal validation of the
PREP-L model
The apparent c-statistic for the PREP-L model (averaged across all multiply imputed data sets) was 0.84
(95% CI 0.82 to 0.87) and after adjustment for optimism it was 0.82 (95% CI 0.80 to 0.84). A sensitivity
analysis showed that when all predictors were added to the final model, the c-statistic increased by < 0.01.
Another sensitivity analysis of the model using oral and parenteral antihypertensive drugs separately
showed no change in the c-statistic; therefore, the combined antihypertensive variable was retained.
The addition of log-transformed serum uric acid concentration increased the c-statistic by < 0.004.
The predicted risk was grouped into tenths defined by centiles of predicted risk. Table 13 shows the
proportions of outcomes observed within each centile of risk. Figure 3 shows predicted versus observed
risk in the model development data set PREP.
TABLE 12 Final PREP-L model including non-linear FP terms before optimism adjustment
Candidate predictors Odds ratio (95% CI) p-value
Maternal age (years) 0.977 (0.950 to 1.004) 0.099
FP (log-gestational age at diagnosis)3 1,188,051.840
(29,739.511 to 47,461,008.565)
< 0.001
FP (log-gestational age at diagnosis)3 × ln(log-gestational age at diagnosis) 0.000 (0.000 to 0.001) < 0.001
Effect of one pre-existing condition 0.681 (0.467 to 0.994) 0.046
Effect of more than two pre-existing conditions 0.510 (0.295 to 0.884) 0.016
Systolic BP (mmHg) 1.028 (1.017 to 1.039) < 0.001
Platelet count (× 109/l) 0.995 (0.993 to 0.997) < 0.001
FP (log-serum urea concentration)–1 0.332 (0.191 to 0.575) < 0.001
Log-transformed PCR 1.185 (1.030 to 1.362) 0.019
Baseline treatment: any antihypertensive drug 1.607 (1.085 to 2.380) 0.018
Baseline treatment: magnesium sulphate 4.279 (1.963 to 9.325) < 0.001
Constant 0.000 (0.000 to 0.000) < 0.001
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Final adjusted PREP-L model for adverse maternal outcomes in
women with early-onset pre-eclampsia
Based on the optimism in calibration, the predictor effect estimates of the developed model coefficient
were reduced by the uniform shrinkage factor of 0.862. Appendix 6 shows the coefficient for the final
logistic model adjusted for optimism.
TABLE 13 Proportions of outcomes within groups of predicted risk in the PREP-L model
Centile of risk Women, n Outcomes observed, n (%)
< 10th centile 11 3 (27)
10–20th centile 35 11 (31)
20–30th centile 58 15 (26)
30–40th centile 78 20 (26)
40–50th centile 80 34 (43)
50–60th centile 92 47 (51)
60–70th centile 87 54 (62)
70–80th centile 122 86 (70)
80–90th centile 159 144 (91)
> 90th centile 224 219 (98)
0.0
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FIGURE 3 Predicted versus observed risk for maternal complications in the PREP-L model. Reproduced from
Thangaratinam S, Allotey J, Marlin N, Dodds J, Cheong-See F, von Dadelszen P, et al. Prediction of complications in
early-onset pre-eclampsia (PREP): development and external multinational validation of prognostic models. BMC
Med 2017;15:68. This article is distributed under the terms of the Creative Commons Attribution 4.0 International
License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction
in any medium, provided that appropriate credit to the original authors and the source is given.40
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Based on the women’s characteristics the probability of adverse outcome by discharge is:
Pr(outcome)=exp (X )=(1+exp (X )), (4)
where:
X=β1×x1+…+βn×xn. (5)
β1–βn are the coefficients for predictors in Appendix 6. Written formally, the equation used to derive
individual risk predictions by discharge is as shown in Box 3.
The predicted probability of an outcome is exp(X)/(1 + exp(X)), where X is the predicted logit-p.
Application of the PREP-L model
We have shown examples of application of the PREP-L model below for two women recruited in the
PREP study.
Scenario 1
BVH007, a 24-year-old woman with no relevant medical history, was admitted with a diagnosis of
pre-eclampsia at 33 + 6 weeks’ gestation. Her highest systolic BP was 200 mmHg and her urine PCR was
4907.6 mg/mmol. Her blood profile showed a platelet count of 75 × 109/l and a serum urea concentration
of 9.5 mmol/l. She required parenteral antihypertensive therapy to manage her BP and was started on
magnesium sulphate by her clinicians.
Applying the equation exp(3.649)/[1 + exp(3.649)], her predicted risk of adverse maternal outcome by
discharge was 97%. The mother was observed to need a blood transfusion following an emergency
caesarean section as a result of worsening pre-eclampsia at 9 hours after diagnosis (Table 14).
BOX 3 Calculation of outcome risk by discharge
X=−0:020 × maternal age
+ 12:052×(log (GA))3−39:90241)
−7:930×((log (GA))3 × log(log (GA)−49:08188)
−0:330 (if one pre-existing condition)
−0:579 (if two or more pre-existing conditions)
+ 0:146× log(PCR)
−0:951× log(serum urea concentration)−1
 
−0:004×platelet count
+ 0:024×SBP
+ 0:409 (if baseline treatment with antihypertensive drug)
+ 1:252 (if baseline treatment with MgSO4)
−1:507
Pr(outcome)=exp(X )=(1+exp(X )).
GA, gestational age; MgSO4, magnesium sulphate; SBP systolic BP.
DOI: 10.3310/hta21180 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 18
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Thangaratinam et al. under the terms of a commissioning contract issued by the Secretary of State
for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
33
TA
B
LE
14
Ex
am
p
le
s
o
f
ca
lc
u
la
ti
o
n
o
f
ri
sk
o
f
ad
ve
rs
e
m
at
er
n
al
o
u
tc
o
m
e
b
y
d
is
ch
ar
g
e
u
si
n
g
th
e
PR
EP
-L
m
o
d
el
Pr
ed
ic
to
r
va
ri
ab
le
s
Ex
am
p
le
1:
B
V
H
00
7
Ex
am
p
le
2:
B
W
H
01
2
Pr
ed
ic
to
r
va
lu
es
C
al
cu
la
ti
o
n
Pr
ed
ic
to
r
va
lu
es
C
al
cu
la
ti
o
n
M
at
er
na
la
ge
(y
ea
rs
)
24
–
0.
02
0
×
24
–
0.
48
0
28
–
0.
02
0
×
28
–
0.
56
0
Su
m
m
ar
y
sc
or
e
of
m
ed
ic
al
hi
st
or
y
0
+
0
+
0
1
+
1
+
1
G
es
ta
tio
na
la
ge
(w
ee
ks
)
at
di
ag
no
si
s
33
.8
57
+
12
.0
52
×
{[l
og
(3
3.
85
7)
]3
–
39
.9
02
41
}
–
7.
93
0
×
[lo
g(
33
.8
57
)]3
×
lo
g{
[lo
g(
33
.8
57
)]
–
49
.0
81
88
}
–
1.
34
4
32
.8
57
+
12
.0
52
×
{[l
og
(3
2.
85
7)
]3
–
39
.9
02
41
}
–
7.
93
0
×
[lo
g(
32
.8
57
)]3
×
lo
g{
[lo
g(
32
.8
57
)]
–
49
.0
81
88
}
–
0.
74
4
PC
R
(m
g/
m
m
ol
)
49
07
.6
+
0.
14
6
×
lo
g(
49
07
.6
)
+
1.
24
1
0.
32
+
0.
14
6
×
lo
g(
0.
32
)
–
0.
16
6
Se
ru
m
ur
ea
co
nc
en
tr
at
io
n
(m
m
ol
/l)
9.
5
–
0.
95
1
×
[lo
g(
9.
5)
–
1]
–
0.
42
2
3.
5
–
0.
95
1
×
[lo
g(
3.
5)
–
1]
–
0.
75
9
Pl
at
el
et
co
un
t
(×
10
9 /
l)
75
–
0.
00
4
×
75
–
0.
30
0
28
3
–
0.
00
4
×
28
3
–
1.
13
2
Sy
st
ol
ic
BP
(m
m
H
g)
20
0
+
0.
02
4
×
20
0
+
4.
80
0
13
6
+
0.
02
4
×
13
6
+
3.
26
4
B
as
el
in
e
tr
ea
tm
en
t
A
ny
an
tih
yp
er
te
ns
iv
e
dr
ug
1
(‘y
es
’)
+
0.
40
9
+
0.
40
9
1
(‘y
es
’)
+
0.
40
9
+
0.
40
9
M
ag
ne
si
um
su
lp
ha
te
1
(‘y
es
’)
+
1.
25
2
+
1.
25
2
0
(‘n
o’
)
+
0
+
0
–
1.
50
7
–
1.
50
7
=
3.
64
9
=
–
1.
52
5
Pr
ed
ic
te
d
ris
k
by
di
sc
ha
rg
e
0.
97
6
0.
17
9
A
dv
er
se
m
at
er
na
lo
ut
co
m
es
Bl
oo
d
tr
an
sf
us
io
n
w
ith
in
9
ho
ur
s
of
di
ag
no
si
s
N
on
e
PREDICTION OF RISK OF ADVERSE MATERNAL OUTCOME BY DISCHARGE: PREP-L MODEL
NIHR Journals Library www.journalslibrary.nihr.ac.uk
34
Scenario 2
BWH012, a 28-year-old woman, was admitted with a diagnosis of pre-eclampsia at 32 + 6 weeks’
gestation. She had a summary score of 1 for relevant medical history and her highest systolic BP was
136 mmHg. Her PCR was 0.32 mg/mmol and her blood profile showed a platelet count of 283 × 109/l
and a serum urea concentration of 3.5 mmol/l. She was started on parenteral antihypertensives by her
clinician to manage her BP.
Applying the equation, exp (–1.525)/[1 + exp(–1.525)], her predicted risk of adverse maternal outcome
by discharge was 18%. The mother was discharged without having any adverse maternal outcome
(see Table 14).
Sensitivity analysis of the PREP-L model in participants with
unconfirmed diagnosis of pre-eclampsia
Of the 142 participants recruited with a suspected diagnosis of pre-eclampsia, 138 had a 1+ urine dipstick.
There were two perfect predictions by baseline treatment with magnesium sulphate and these two
observations were dropped. The optimism-adjusted logistic model, as described in Appendix 6, was applied
to 136 women with an unconfirmed diagnosis of pre-eclampsia. The apparent c-statistic was 0.68 (95% CI
0.58 to 0.79) and the calibration slope was 0.64 (95% CI 0.25 to 1.04).
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Chapter 5 Prediction of adverse maternal outcome
in women with early-onset pre-eclampsia: PREP-S
model
Overall, 946 women contributed towards 584 failures. Five of these failures occurred on the same dayas diagnosis and were forced into the survival model by adding 10 minutes to the time of their
occurrence. The total analysis time at risk was 10,923 days, the median analysis time per participant was
6 days (interquartile range 2–14 days) and the longest follow-up period is 98 days. The mean gestational
age at delivery was 33.0 weeks (SD 3.2 weeks). For the survival model, the first adverse events are defined
as the failure event and are shown in Table 15. Delivery before 34 weeks’ gestation contributed the most
(85%, 497/584) to failures.
Modelling continuous predictors
We modelled the continuous predictors as shown in Chapter 4, Modelling continuous predictors.
Development of the PREP-S model: predictor selection
Table 16 shows the hazard ratios for adverse pregnancy outcomes for various candidate predictors by
univariable and by multivariable analysis summarised across using the multiply imputed data sets.
TABLE 15 Rates of failure defining adverse events for the survival model
Failure defining adverse event Number of women (N= 584), n (%)
Eclamptic seizures after diagnosis 11 (1.9)
Glasgow Coma Scale score of < 13 1 (0.2)
Hepatic dysfunction 4 (0.7)
At least 50% FiO2 for > 1 hour 1 (0.2)
Intubation 1 (0.2)
Pulmonary oedema 4 (0.7)
Transfusion of any blood product 12 (2.1)
Abruption 16 (2.7)
PPH 31 (5.3)
Delivery at < 34 weeks’ gestational age 497 (85.1)
Combined events
Acute renal insufficiency and preterm delivery (< 34 weeks’ gestation) 1 (0.2)
Abruption and preterm delivery (34 weeks’ gestation) 3 (0.5)
Intubation, PPH and transfusion of any blood product 1 (0.2)
Abruption and PPH 1 (0.2)
FiO2, fraction of inspired oxygen; PPH, postpartum haemorrhage.
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After dropping the candidate predictor variables stepwise based on the largest p-value, the following were
included as the final list of predictors in the survival model: maternal age, log-transformed gestational age
at diagnosis, summary score for medical history, systolic BP, clonus, exaggerated tendon reflexes, oxygen
saturation, platelet count, log-transformed ALT concentration, log-transformed serum urea concentration,
log-transformed serum creatinine concentration, log-transformed PCR, baseline treatment with any
antihypertensive drug and baseline treatment with magnesium sulphate.
We identified non-linear terms for log-transformed gestational age at diagnosis and serum urea
concentration using FPs. We chose terms with a p-value of > 0.001 to avoid overfitting. After including
non-linear terms for gestational age at diagnosis and serum urea concentration, clonus then filled the
criterion for exclusion at a p-value of > 0.150 and was therefore removed. Running the multivariable FP
procedure without clonus confirmed that the FP terms identified originally were still valid (results not shown).
In the full multivariable model, the risk of adverse maternal outcomes were significantly increased at the
5% level with lower maternal age, greater gestational age at diagnosis, lower number of components of
medical history, raised systolic BP, lower platelet count, raised ALT concentration, raised serum urea
concentration, increased urine PCR and administration of magnesium sulphate.
We applied the variable selection process and included the non-linear terms for gestational age at diagnosis and
serum urea concentration. The PREP-S survival model prior to adjustment for optimism is shown in Table 17.
Apparent performance of the PREP-S model
The apparent c-statistic of the developed survival model was 0.78 (95% CI 0.76 to 0.80). Estimation of
risks in the five groups defined by the 10th, 25th, 75th and 90th centiles of predicted risk showed that the
probability of adverse outcome was around 52% in the highest risk group at 48 hours after diagnosis,
95% by 1 week, and 100% by 1 month. Ninety-seven per cent (91/94) of women in the > 90th centile
group experienced an adverse maternal outcome, with a mean follow-up time of 1.2 days (SD 1.3 days).
In the lowest risk group (≤ 10th centile), the probability of outcome-free survival was around 97% at
48 hours after diagnosis, 87% by 1 week, and 56% by 1 month. In this group, 24% (23/95) had an
adverse outcome, with a mean follow-up time of 28.9 days (SD 23.1 days) (Table 18).
In women in the groups defined by the highest centiles of predicted risk, there was good agreement
between those with observed and predicted adverse outcomes. About 97% (91/94) of women with risks
above the 90th centile had an adverse outcome; 83% (118/143) of women with predicted risks between
the 75th and 90th centiles had complications; and 61% (289/471) with risks between the 25th and 75th
centiles experience an adverse outcome.
Figure 4 shows the model-based mean survival curves for the five prognostic groups compared with their
observed Kaplan–Meier survival curves, for 1 month after diagnosis-days. Agreement is generally excellent,
perhaps with the exception of the lowest risk group, although this has fewest events and so more
uncertainty about the mean predicted curve. CIs are not shown on the figure for aesthetic reasons.
Sensitivity analysis
Inclusion of all candidate predictors in the model only improved the Harrell’s c-statistic by < 0.001.
Comparison of the Cox regression model with our flexible parametric model yielded similar hazard ratios,
as expected. The full models are presented in Appendix 7. Time-dependent effects on the model were
not significant for all covariates except baseline medication. Inclusion of this effect for baseline medication
into the model improved Harrell’s c-statistic by 0.005 (results not shown). In order to avoid overfitting
and achieve simplicity, we considered this improvement too small to include a time-dependent effect into
our final model. Another sensitivity analysis of the model using oral and parenteral antihypertensive therapy
separately showed no change in the c-statistic; therefore, the combined antihypertensive variable was
retained. Addition of log-transformed uric acid concentration changed the Harrell’s c-statistic by < 0.001.
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TABLE 17 Final PREP-S model including non-linear FP terms before adjustment for optimism
Flexible parametric model after multiple imputation Hazard ratio 95% CI p-value
Maternal age (years) 0.964 0.951 to 0.978 < 0.001
FP [log(GA at diagnosis/10)]–2 centred at 0.8345136 5.794 0.299 to 112.276 0.245
aFP [log(GA at diagnosis/10)]–2 ln[log(GA at diagnosis/10)] centred
at 0.0652155
750.276 2.380 to 236561.167 0.024
Exaggerated tendon reflexes 1.152 0.935 to 1.420 0.185
Number of pre-existing conditions
0
Effect of a medical history score of 1 0.822 0.668 to 1.010 0.062
Effect of a medical history score of ≥ 2 0.640 0.464 to 0.883 0.007
Systolic BP (mmHg) 1.018 1.013 to 1.023 < 0.001
Oxygen saturation < 94% 2.520 0.870 to 7.298 0.089
Platelet count (× 109/l) 0.997 0.996 to 0.998 < 0.001
Log-transformed ALT concentration 1.157 1.031 to 1.299 0.013
FP (log-serum urea concentration)2 2.017 1.611 to 2.526 < 0.001
FP (log-serum urea concentration)3 0.846 0.795 to 0.900 < 0.001
Log-transformed serum creatinine concentration centred at 4.067578 1.361 0.952 to 1.944 0.091
Log-transformed PCR 1.097 1.025 to 1.173 0.007
Baseline treatment
Any antihypertensive drug 1.227 0.976 to 1.543 0.080
Magnesium sulphate 3.445 2.675 to 4.437 < 0.001
GA, gestational age.
a Spline basis functions not shown.
TABLE 18 Survival time within groups of predicted risk
Centile of predicted risk Number of women, n Adverse maternal outcome, n (%)
Follow-up time (days),
mean (SD)
Adverse
outcome
No adverse
outcome
≤ 10th 95 22 (23) 28.2 (23.3) 40.2 (29.8)
10–25th 143 64 (45) 16.1 (12.7) 15.9 (13.7)
25–75th 471 289 (61) 8.6 (8.4) 10.1 (9.4)
75–90th 143 118 (83) 3.9 (4.4) 6.3 (5.9)
> 90th 94 91 (97) 1.2 (1.3) 3.7 (4.6)
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Internal validation and shrinkage of estimates for the final
PREP-S model
The bootstrap approach showed an optimism of 0.019 (SD 0.010) in the c-statistic and 0.138 (SD 0.002) in
the calibration slope. Based on the optimism in calibration, the predictor effect estimates of the developed
model coefficient were reduced by the uniform shrinkage factor: 1 – 0.138 = 0.862. The intercept of the
baseline spline term was re-estimated to ensure perfect calibration-in-the-large. The optimism-adjusted
Harrell’s c-statistic of the survival model was 0.75 (95% CI 0.73 to 0.78).
Appendix 8 shows the coefficients of the final PREP-S model and the baseline hazard after adjusting for
optimism. Table 19 gives the baseline survival at various time points to calculate the predicted survival
probability for a woman diagnosed with early-onset pre-eclampsia.
Based on the woman’s characteristics, the survival probability at time point t is:
S(t) = S0(t)
exp ½(β1 × X1 +… + βn × Xn), (6)
where β1–βn are the coefficients for predictors shown in Appendix 8, and X1–Xn are the predictor values for the
patient. Written formally, the equation used to derive individual risk predictions over time is shown in Box 4.
Positive regression coefficients suggest an increase in the risk of adverse maternal outcome with increasing
values of continuous predictors or the presence of dichotomous predictor variables, and vice versa for
negative coefficients.
Application of the PREP-S model
We have provided examples of calculating the individual risk of adverse maternal outcomes at 48 hours
using the PREP-S model. The predictor values of two women are provided in Table 20. The calculation of
risk can easily be amended to a different time point by replacing the value for baseline survival with the
baseline survival for the desired time point from Table 18.
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FIGURE 4 Mean survival curves for groups of prognostic index compared with their observed Kaplan–Meier survival
curves up to 30 days from diagnosis. Reproduced from Thangaratinam S, Allotey J, Marlin N, Dodds J, Cheong-See F,
von Dadelszen P, et al. Prediction of complications in early-onset pre-eclampsia (PREP): development and external
multinational validation of prognostic models. BMC Med 2017;15:68. This article is distributed under the terms of
the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which
permits unrestricted use, distribution and reproduction in any medium, provided that appropriate credit to the
original authors and the source is given.40
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Sensitivity analysis of survival model in participants with
unconfirmed diagnosis of pre-eclampsia
Of the 142 participants recruited with a suspected diagnosis of pre-eclampsia, 138 had a 1+ urine dipstick.
For one woman the time of outcome was missing. The optimism-adjusted survival model, as described in
Appendix 8, was applied to this population. The apparent c-statistic was 0.64 (95% CI 0.53 to 0.76) and
the calibration scope was 0.88 (95% CI 0.17 to 1.58).
TABLE 19 Baseline survival adjusted for optimism at various time points for women diagnosed with early-onset
pre-eclampsia
Time point (days) Baseline survival, S0(t)
2 0.99142
3 0.98542
4 0.97973
5 0.97452
6 0.96962
7 0.96492
14 0.93404
21 0.90373
28 0.87377
35 0.84432
42 0.81549
BOX 4 Calculation of risk predictions over time
S(t)=
S0(t)
exp(−0:031×maternal age)
+ 1:514×((log (GA at diagnosis=10))−2 − 0:8345136)
+ 5:707 × (log(GA at diagnosis=10))−2 × ln (log(GA at diagnosis=10)) − 0:0652155)
+ 0:122 (if exaggerated tendon reflexes=1)
− 0:169 (if one pre-existing condition)
− 0:384 (if ≥ 2 pre-existing conditions)
+ 0:016×systolic BP
+ 0:797 (if pulse oximetry < 94%)
− 0:002×platelet count
+ 0:126× log(ALT concentration)
+ 0:605× log(serum urea concentration)2
− 0:144× log(serum urea concentration)3
+ 0:265× log(serum creatinine concentration)
+0:080× log(PCR)
+ 0:176 (if baseline treatment with any antihypertensive drug)
+ 1:066 (if baseline treatment with magnesium sulphate).
where S0(t) is the value of the baseline survival function at time t (see Table 19).
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Chapter 6 External validation of the prediction
models for complications in women with early-onset
pre-eclampsia
Inclusion criteria and availability of data in external data sets
The PIERS study
The PIERS study evaluated the effects of 48 predictors in 2023 women with pre-eclampsia of any onset.
Of these, 636 (31%) were diagnosed with early-onset pre-eclampsia and 634 had available data for
external validation of the PREP models. The majority of women with early-onset pre-eclampsia
were classified as having new-onset disease (519/636, 82%), followed by those with superimposed
pre-eclampsia (95/636, 15%) and HELLP syndrome (22/636, 3%) (Table 21).
Of the 13 predictors in the PREP models, 10 were also evaluated in the PIERS study. Exaggerated tendon
reflexes, serum urea concentration and autoimmune diseases (one element of the medical history) were
assessed in the PREP study, but were not available in the PIERS data set.
The PETRA study
The PETRA study evaluated the effect of plasma volume expansion in 111 patients with severe hypertensive
disorders of pregnancy compared with a control group of 105 patients with severe hypertensive disorders of
pregnancy. All patients (n = 216) had a diagnosis of early-onset pre-eclampsia and had available data for
external validation of the PREP-L model only. The majority of women with early-onset pre-eclampsia were
those classified as having fetal growth restriction or pregnancy-induced hypertension (125/216, 58%),
followed by those with new-onset pre-eclampsia (96/216, 44%), HELLP syndrome (54/216, 25%) and
eclampsia (5/216, 2.3%) (see Table 21).
TABLE 21 Inclusion criteria for women with early-onset pre-eclampsia recruited to the PIERS and PETRA studies
compared with the PREP cohort
Inclusion criteria
Study
Women in the PREP
cohort (N= 954),
n (%)
Women in the PIERS
cohort (N= 636),
n (%)
Women in the PETRA
cohort (N= 216),
n (%)
New-onset pre-eclampsia 866 (91.0) 519 (82) 96 (44)a
Chronic hypertension 75 (7.9)
Superimposed pre-eclampsia 10 (1.0) 95 (15)
HELLP syndrome 3 (0.3) 22 (3) 54 (25)a
Eclampsia 5 (2.3)a
Fetal growth restriction or
pregnancy-induced hypertension
125 (58)a
a Some patients matched more than one inclusion diagnosis.
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Characteristics of women with early-onset pre-eclampsia in the
PIERS and PETRA studies
There were no significant differences in the mean gestational age at diagnosis of pre-eclampsia, which was
around 30 weeks. The PETRA study included only singleton pregnancies, while around 91% (870/954)
of pregnancies in the PREP study and 85% (542/634) in the PIERS study were singletons. Two-thirds
(601/953, 63%) of women in the PREP study did not have any significant medical history, such as
pre-existing medical conditions or previous history of pre-eclampsia, compared with 45% (284/634) and
84% (182/216) in the PIERS and PETRA studies, respectively.
The PETRA study did not have any data on symptoms or examination findings such as deep-tendon
reflexes or clonus. In addition, the study did not report any tests for proteinuria, oxygen saturation and
serum creatinine concentration that were reported in the other two cohorts. Table 22 compares patient
characteristics and candidate predictor variables in the PREP development data set and the PIERS and
PETRA validation data sets.
Risk of adverse outcomes in the PIERS and PETRA cohorts
Overall, 67% (633/946) of women with early-onset pre-eclampsia in the PREP study had adverse maternal
outcomes by discharge, compared with 77% (489/634) and 86% (185/216) in the PIERS and PETRA
cohorts, respectively. The date and time of occurrence of adverse maternal outcomes was consistently
reported in the PIERS data set and not in the PETRA study. Maternal and fetal composite outcomes not
reported in the PIERS and PETRA data sets are provided in Tables 23 and 24.
External validation of the models
As not all predictors in the PREP models were available in the PIERS and PETRA data sets, we externally
validated a slightly reduced version of our final models, with the model parameters re-estimated with a
reduced set of predictors. We re-estimated the coefficients and intercept terms of the model, and then
adjusted for optimism as before. We validated the survival model in only the PIERS data set, because
of the non-availability of time of outcome occurrence in the PETRA cohort.
External validation of the PREP-L model in the PIERS data set
Complete records on the predictors considered were available for 437 of 654 women in whom
pre-eclampsia was diagnosed at < 34 weeks’ gestation.
Obtaining the reduced PREP-L model
Serum urea concentration was identified as a predictor in the PREP data, but it was not recorded in the
PIERS data set. We obtained the reduced PREP-L (rPREP-L) model and adjusted for optimism after excluding
serum urea concentration (see Appendix 9). The calibration slope for this optimism-adjusted rPREP-L model
was 1.01 (95% CI 0.86 to 1.15) when averaged across all imputed data sets. The apparent c-statistic was
0.82 (95% CI 0.80 to 0.85).
Application of the reduced PREP-L model in the PIERS data set
The optimism-adjusted c-statistic of the rPREP-L model was 0.81 (95% CI 0.77 to 0.85), indicating a good
discrimination in the external validation data set. The calibration slope was 0.93 (95% CI 0.72 to 1.13),
indicating very good calibration and model fit in the PIERS data on average across all individuals (Figure 5).
The predicted risk was grouped into centiles of predicted risk. Table 25 shows the risk of outcome for each
centile of predicted risk. When the intercept term was recalibrated to the PIERS data, the calibration slope
and c-statistic remained the same.
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TABLE 22 Characteristics of women with early-onset pre-eclampsia in the PREP study and external validation
cohorts (PIERS and PETRA)
Characteristics
of women
Study
PREP PIERS PETRA
Women
for whom
data were
available (n)
Mean (SD)
or n (%)
Women
for whom
data were
available (n)
Mean (SD)
or n (%)
Women
for whom
data were
available (n)
Mean (SD)
or n (%)
Gestational age at
diagnosis (weeks),
mean (SD)
954 30.5 (2.9) 634 30.2 (3.0) 216 29.4 (2.6)
Maternal characteristics
Maternal age (years),
mean SD
952 30.2 (6.1) 634 31.2 (6.3) 216 30.0 (5.0)
Number of fetuses
in pregnancy
954 634 216
Singleton 866 (91%) 542 (85%) 216 (100%)
Twins 83 (9%) 88 (14%) –
Triplets 5 (1%) 4 (1%) –
History
Summary score for
medical history
953 634 216
0 601 (63%) 284 (45%) 182 (84%)
1 251 (26%) 251 (40%) 30 (14%)
≥ 2 101 (11%) 99 (15%) 4 (2%)
Symptoms
Headache and/or
visual disturbance,
present
926 382 (41%) 634 319 (50%) – –
Epigastric pain,
nausea and/or
vomiting, present
907 202 (22%) 634 220 (35%) – –
Chest pain and/or
dyspnoea, present
828 60 (7%) 634 42 (7%) – –
Examination
Clonusa 551 95 (17%) – – – –
Exaggerated tendon
reflexes,a mean (SD)
601 139 (15%) – – – –
Systolic BP, mean (SD) 949 159 (19) 634 168 (20) 216 157 (18)
Diastolic BP, mean (SD) 949 99 (12) 634 105 (11) 216 104 (11)
Oxygen saturation by
pulse oximetry (%),
mean (SD)
433 98.1 (1.6) 474 96 (2) – –
Oxygen saturation
abnormal (< 94%),
present
433 4 (1%) 474 72 (15%) – –
continued
DOI: 10.3310/hta21180 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 18
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Thangaratinam et al. under the terms of a commissioning contract issued by the Secretary of State
for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
49
TABLE 22 Characteristics of women with early-onset pre-eclampsia in the PREP study and external validation
cohorts (PIERS and PETRA) (continued )
Characteristics
of women
Study
PREP PIERS PETRA
Women
for whom
data were
available (n)
Mean (SD)
or n (%)
Women
for whom
data were
available (n)
Mean (SD)
or n (%)
Women
for whom
data were
available (n)
Mean (SD)
or n (%)
Laboratory tests
Haemoglobin (g/l),
mean (SD)
917 11.9 (1.3) – – – –
Platelet count
(× 109/l), mean (SD)
913 226 (78) 630 204 (77) 215 172 (87)
ALT concentration
(U/l), mean (SD)
879 31.0 (71.0) 630 65.5 (157.6) 207 79.9 (139.3)
AST concentration
(U/l), mean (SD)
275 36.9 (61.1) 600 74.3 (196.5) 212 91.9 (160.7)
Serum uric acid
concentration (µmol/l),
mean (SD)
789 0.6 (2.7) – – – –
Serum urea
concentration
(mmol/l), mean (SD)
884 4.6 (4.4) – – – –
Serum creatinine
concentration (µmol/l),
mean (SD)
916 61.9 (17.8) 626 69.3 (20.5) 214 67.8 (16.8)
Urine dipstick
None/trace 935 39 (4%) 613 129 (21%) – –
1+ 170 (18%) 69 (11%) – –
2+ 314 (34%) 111 (18%) – –
3+ 306 (33%) 141 (23%) – –
≥ 4 106 (11%) 163 (27%) – –
Urine PCR 24 hour
(mg/mmol), mean (SD)
433 98.1 (1.6) 437 276 (437) – –
Baseline treatment
Antihypertensive
therapy, present
948 753 (79%) 634 551 (87%) 216 123 (57%)
Magnesium sulphate
administration,
present
948 144 (15%) 634 325 (51%) 216 34 (16%)
a Predictor is part of the survival model only and used as a component of the final PREP model.
Reproduced from Thangaratinam S, Allotey J, Marlin N, Dodds J, Cheong-See F, von Dadelszen P, et al. Prediction of
complications in early-onset pre-eclampsia (PREP): development and external multinational validation of prognostic models.
BMC Med 2017;15:68. This article is distributed under the terms of the Creative Commons Attribution 4.0 International
License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any
medium, provided that appropriate credit to the original authors and the source is given.40
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TABLE 23 Comparison of the maternal outcome measures in the PIERS and PETRA data sets compared with the
PREP study
Components of adverse maternal outcome evaluated in the PREP study PIERS PETRA
Maternal death ✓ ✓
Eclamptic seizures ✓ ✓
Glasgow Coma Scale score of < 13 ✓ ✓
Stroke or RIND ✓ ✓
Cortical blindness ✓ ✓
Retinal detachment – –
Posterior reversible encephalopathy – ✓
Bell’s palsy ✓ –
Hepatic dysfunction ✓ ✓
Subcapsular haematoma – –
Hepatic rupture ✓ ✓
Need for positive inotrope support ✓ –
Myocardial ischaemia or infarction ✓ –
At least 50% FiO2 for > 1 hour ✓ ✓
Intubation ✓ ✓
Pulmonary oedema ✓ ✓
Acute renal insufficiency (creatinine concentration of > 200 uM) ✓ ✓
Dialysis ✓ ✓
Transfusion of any blood product ✓ ✓
Abruptions – ✓
Postpartum haemorrhage – ✓
Delivery at < 34 weeks’ gestational age ✓ ✓
FiO2, fraction of inspired oxygen; RIND, reversible ischaemic neurological deficit.
TABLE 24 Comparison of the fetal outcome measures in the PIERS and PETRA data sets
Components of adverse fetal outcome evaluated in the PREP study PIERS PETRA
Neonatal death ✓ ✓
Bronchopulmonary dysplasia ✓ ✓
Necrotising enterocolitis ✓ ✓
Grade III/IV intraventricular haemorrhage ✓ ✓
Cystic periventricular leukomalacia ✓ ✓
Stage 3–5 retinopathy ✓ –
Hypoxic–ischaemic encephalopathy – ✓
Stillbirth ✓ ✓
Admission to NICU at any time ✓ ✓
NICU, neonatal intensive care unit.
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External validation of the reduced PREP-L model in the PETRA cohort
Complete records on the predictors considered were available for 211 of 216 women in whom
pre-eclampsia was diagnosed at < 34 weeks’ gestation .
Harrell’s c-statistic was 0.75 (95% CI 0.64 to 0.86), indicating a moderate discrimination in the external
validation data set. The calibration slope was 0.90 (95% CI 0.48 to 1.3), indicating some slight
0.0
0.0
0.2
0.4
0.6
0.8
1.0
0.2 0.4 0.6
Risk of outcome predicted
R
is
k 
o
f 
o
u
tc
o
m
e 
o
b
se
rv
ed
0.8 1.0
FIGURE 5 Validation plot of the predicted vs. observed risk for adverse maternal outcome using the rPREP-L model in
the PIERS cohort. Reproduced from Thangaratinam S, Allotey J, Marlin N, Dodds J, Cheong-See F, von Dadelszen P, et al.
Prediction of complications in early-onset pre-eclampsia (PREP): development and external multinational validation of
prognostic models. BMC Med 2017;15:68. This article is distributed under the terms of the Creative Commons
Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution and reproduction in any medium, provided that appropriate credit to the original authors and the
source is given.40
TABLE 25 Comparison of the predicted vs. observed risk for adverse maternal outcome using the rPREP-L model in
the PIERS cohort
Groups of predicted risk Women with predicted outcomes, n Women with observed outcomes, n (%)
< 10th centile 0 –
10–20th centile 3 0 (0)
20–30th centile 20 6 (30)
30–40th centile 24 8 (33)
40–50th centile 33 16 (48)
50–60th centile 34 21 (62)
60–70th centile 38 19 (50)
70–80th centile 58 42 (72)
80–90th centile 72 59 (82)
> 90th centile 155 147 (95)
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miscalibration, with observed risk generally higher than predicted. However, predictions showed
reasonably close agreement at predicted risks above 0.7 (Figure 6). Table 26 shows the risk of outcome for
groups defined by tenths of predicted risk.
Recalibration of the intercept to the PETRA data did not improve the calibration slope. Table 27 shows the
performance of the reduced PREP models in the derivation cohorts and external validation data sets.
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FIGURE 6 Validation plot of the predicted vs. observed risk for adverse maternal outcome using the rPREP-L model
in the PETRA cohort. Reproduced from Thangaratinam S, Allotey J, Marlin N, Dodds J, Cheong-See F, von Dadelszen P,
et al. Prediction of complications in early-onset pre-eclampsia (PREP): development and external multinational
validation of prognostic models. BMC Med 2017;15:68. This article is distributed under the terms of the Creative
Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits
unrestricted use, distribution and reproduction in any medium, provided that appropriate credit to the original
authors and the source is given.40
TABLE 26 Comparison of predicted vs. observed risk for adverse maternal outcome using the rPREP-L model in the
PETRA cohort
Groups of predicted risk Women with predicted outcomes, n Women with observed outcomes, n (%)
< 10th centile 0 –
10–20th centile 0 –
20–30th centile 4 2 (50)
30–40th centile 1 1 (100)
40–50th centile 11 4 (36)
50–60th centile 13 8 (62)
60–70th centile 22 18 (82)
70–80th centile 30 25 (83)
80–90th centile 74 70 (95)
> 90th centile 56 52 (93)
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External validation of the PREP-S model in the PIERS data set
In the PIERS data set, 634 women were diagnosed with pre-eclampsia before 34 weeks’ gestation.
Four hundred and sixty-one failures occurred during follow-up, six of which occurred on the same day as
diagnosis and were included by adding a fraction of a day. One hundred and thirty-two had failures by
48 hours, 332 by 1 week and 458 by 30 days after diagnosis. We evaluated the reduced PREP-S (rPREP-S)
model in 339 women with complete predictor value data. The total analysis time was 5425 days, with
the last observed exit at 89 days of follow-up.
Obtaining the reduced PREP-S model
As serum urea concentration and exaggerated tendon reflexes were identified to be a predictor in the
PREP-S model but were not recorded in the PIERS data set, we refitted the PREP-S model. Appendix 10
shows the coefficients of the rPREP-S prediction model after excluding serum urea concentration and
exaggerated tendon reflexes, adjusted for optimism. Harrell’s c-statistic of the optimism-adjusted rPREP-S
model was 0.76 (95% CI 0.74 to 0.78).
Applying the reduced PREP-S model in the PIERS data set
The rPREP-S model with coefficients as described in Appendix 10 was fitted to the PIERS data set.
Figures 7 and 8 compare the predictions made by the PREP model in four prognostic groups of the PIERS
data until 34 weeks’ gestation up to 30 days after diagnosis, respectively.
TABLE 27 Performance of the rPREP-L and rPREP-S models in the derivation cohorts and external validation
data sets
Model performance PREP
rPREP
(for PIERS) PIERS
rPREP
(for PETRA) PETRA
PREP-L model
Number analysed 946 946 437 946 211
Number of outcomes 633 633 318 633 180
Apparent c-statistic (95% CI) 0.84
(0.82 to 0.87)
0.82
(0.80 to 0.85)
0.81
(0.77 to 0.85)
0.81
(0.79 to 0.84)
0.75
(0.64 to 0.86)
Optimism-adjusted c-statistic
(95% CI)
0.82
(0.80 to 0.84)
– – – –
Calibration slope (95% CI) 1 1 0.93
(0.72 to 1.13)
1 0.90
(0.48 to 1.32)
PREP-S model
Number analysed 946 946 339 – –
Number of events 584 584 239 – –
Apparent c-statistic (95% CI) 0.77
(0.75 to 0.79)
0.76
(0.74 to 0.78)
0.71
(0.67 to 0.75)
– –
Optimism-adjusted c-statistic
(95% CI)
0.75
(0.73 to 0.78)
– – – –
Calibration slope (95% CI) 1 1 0.67
(0.56 to 0.79)
– –
rPREP-S, reduced PREP-S.
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The c-statistic in the PIERS cohort was 0.71 (95% CI 0.67 to 0.75), which was slightly lower than that of the
rPREP-S model. However, the four risk groups are still noticeably distinct and ordered appropriately for
the majority of the 30-day period, with the exception of the two intermediate-risk groups before 3 days.
The calibration slope of the rPREP-S model in the PIERS data set was 0.67 (95% CI 0.56 to 0.79), suggesting
large overprediction of the reduced PREP model, and this was observed predominantly in the third of four
groups (which had the largest patient numbers), especially after 5 days. Importantly, those identified as
‘high risk’ by the PREP model were still in the high-risk category in the PIERS cohort, but the observed
absolute risk values were lower than expected from the reduced PREP model.
Calibration slope for each of the four risk groups are:
l ≤ 15th centile (n = 59): 0.21 (95% CI –0.51 to 0.92)
l 15–50th centile (n = 70): 0.65 (95% CI –0.80 to 2.10)
l 50–85th centile (n = 123): 0.25 (95% CI –0.34 to 0.84)
l > 85th centile (n = 87) 0.73 (95% CI 0.42 to 1.00).
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FIGURE 7 Validation of the PREP-S model in the PIERS data set up to 30 days from diagnosis.
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FIGURE 8 Validation of the PREP-S model in the PIERS data set up to 7 days from diagnosis.
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Recalibration of the intercept of the baseline hazard function in the rPREP-S model to the PIERS data set
did not improve calibration. Figure 9 shows that the agreement between observed and predicted survival
was much improved in the high-risk group. However, it was noticeably worse in the other risk groups.
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FIGURE 9 Validation of the rPREP-S model in the PIERS data set after recalibration up to 30 days from diagnosis.
Reproduced from Thangaratinam S, Allotey J, Marlin N, Dodds J, Cheong-See F, von Dadelszen P, et al. Prediction
of complications in early-onset pre-eclampsia (PREP): development and external multinational validation of
prognostic models. BMC Med 2017;15:68. This article is distributed under the terms of the Creative Commons
Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution and reproduction in any medium, provided that appropriate credit to the original authors and the
source is given.40
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Chapter 7 Prediction of fetal complications in
women with early-onset pre-eclampsia
We assessed the predictive value of individual tests on fetal outcomes in the 945 pregnancies for whichoutcome data were available. The rates of individual fetal and neonatal complications observed in
women with early-onset pre-eclampsia can be seen in Table 10.
Performance of the PREP-L model for adverse fetal outcomes
We assessed the performance of the PREP-L model (see Table 12) for the fetal composite outcome, using
the same predictors. Table 28 and Figure 10 show the proportions of outcomes observed within each
centile of risk. The c-statistic was 0.76 (95% CI 0.73 to 0.79) and the calibration slope was 0.77 (95% CI
0.63 to 0.91), indicating overprediction of risk, especially for prediction of 0.6 or below. In women
predicted to be at high risk (> 80th centile), around 90% had adverse fetal outcomes.
Predictive value of tests for adverse fetal and
neonatal outcomes
We evaluated the prognostic value of all candidate predictors associated with maternal outcomes and the
following five additional predictors: ultrasound (uterine artery Doppler in second trimester, expected fetal
weight and liquor volume), CTG findings and use of steroids within or before 24 hours of diagnosis of
pre-eclampsia. Table 29 shows the descriptive values of the candidate predictors and their crude and
multivariate association with adverse fetal outcomes.
Association of maternal and fetal characteristics with adverse
fetal outcomes
In the multivariable analysis of predictors, increased gestational age at diagnosis of pre-eclampsia reduced
the odds of fetal complications (OR 0.09, 95% CI 0.01 to 0.61). A medical history of pre-existing chronic
TABLE 28 Comparison of the number of women with observed adverse fetal outcomes in deciles of risk groups
predicted by the PREP-L model
Decile of risk Women with predicted outcomes, n Women with observed outcomes, n (%)
< 10th centile 7 2 (29)
10–20th centile 23 8 (35)
20–30th centile 53 26 (49)
30–40th centile 73 35 (48)
40–50th centile 91 51 (56)
50–60th centile 101 69 (68)
60–70th centile 103 76 (74)
70–80th centile 140 109 (78)
80–90th centile 171 149 (87)
> 90th centile 183 177 (97)
DOI: 10.3310/hta21180 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 18
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Thangaratinam et al. under the terms of a commissioning contract issued by the Secretary of State
for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
57
0.0
0.0
0.2
0.4
0.6
0.8
1.0
0.2 0.4 0.6
Risk of outcome predicted
R
is
k 
o
f 
o
u
tc
o
m
e 
o
b
se
rv
ed
0.8 1.0
FIGURE 10 Calibration plot of the predicted vs. observed risk for adverse fetal outcome using the PREP-L model.
TABLE 29 Crude univariable and multivariable analyses of candidate predictors and adverse fetal outcomes in
women with early-onset pre-eclampsia
Candidate
predictors Women, na
No adverse
fetal
outcomes
(n= 243),
mean (SD) or
n (%)
Adverse fetal
outcomes
(n= 702),
mean (SD) or
n (%)
Univariable
analysis (N= 945)
Multivariable
analysis (N= 945)
OR (95% CI) p-value OR (95% CI) p-value
Maternal characteristics
Maternal age
(years)
943 31.0 (6.1) 30.0 (6.1) 0.972
(0.949 to 0.995)
0.018 0.984
(0.954 to 1.015)
0.301
Log-transformed
gestational age
(weeks) at
diagnosis
945 3.4 (0.1) 3.4 (0.1) 0.111
(0.022 to 0.554)
0.007 0.089
(0.013 to 0.607)
0.014
Multiple pregnancy
Singleton
(reference)
945 225 (93%) 637 (91%)
Twins 17 (7%) 62 (9%) 1.288
(0.738 to 2.250)
0.373 1.676
(0.862 to 3.260)
0.128
Triplets 1 (0%) 3 (0%) 1.060
(0.110 to 10.239)
0.960 1.245
(0.112 to 13.774)
0.858
Global test 0.673 0.313
Medical history score
0 (reference) 944 116 (48%) 478 (68%)
1 83 (34%) 167 (24%) 0.490
(0.351 to 0.683)
< 0.001 0.654
(0.435 to 0.984)
0.041
≥ 2 44 (18%) 56 (8%) 0.309
(0.198 to 0.481)
< 0.001 0.434
(0.246 to 0.767)
0.004
Global test < 0.001 0.009
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TABLE 29 Crude univariable and multivariable analyses of candidate predictors and adverse fetal outcomes in
women with early-onset pre-eclampsia (continued )
Candidate
predictors Women, na
No adverse
fetal
outcomes
(n= 243),
mean (SD) or
n (%)
Adverse fetal
outcomes
(n= 702),
mean (SD) or
n (%)
Univariable
analysis (N= 945)
Multivariable
analysis (N= 945)
OR (95% CI) p-value OR (95% CI) p-value
Symptoms
Headache and/or
visual disturbance
919 102 (43%) 278 (41%) 0.891
(0.658 to 1.206)
0.456 0.812
(0.552 to 1.193)
0.289
Epigastric pain,
nausea and/or
vomiting
900 43 (19%) 157 (23%) 1.331
(0.906 to 1.955)
0.145 0.958
(0.578 to 1.590)
0.869
Chest pain and/or
dyspnoea
821 12 (6%) 48 (8%) 1.340
(0.668 to 2.687)
0.410 1.190
(0.502 to 2.822)
0.693
Bedside examination and tests
Clonus 545 10 (8%) 84 (20%) 2.399
(1.262 to 4.562)
0.008 1.487
(0.609 to 3.633)
0.384
Exaggerated
tendon reflexes
594 20 (16%) 126 (27%) 2.063
(1.318 to 3.231)
0.002 0.852
(0.461 to 1.575)
0.610
Systolic BP (mmHg) 941 153 (16) 161 (20) 1.025
(1.016 to 1.034)
< 0.001 1.005
(0.992 to 1.019)
0.414
Diastolic BP
(mmHg)
941 96 (11) 101 (11) 1.044
(1.029 to 1.059)
< 0.001 1.018
(0.996 to 1.039)
0.103
Oxygen saturation
abnormal (< 94%)
428 1 (1%) 3 (1%) 1.039
(0.108 to 10.032)
0.974 0.107
(0.009 to 1.214)
0.071
Urine dipstick:
none/trace
(reference)
927
11 (5%) 28 (4%)
1+ 71 (30%) 98 (14%) 0.549
(0.256 to 1.179)
0.124 0.609
(0.259 to 1.435)
0.257
2+ 100 (42%) 212 (31%) 0.840
(0.401 to 1.760)
0.644 0.781
(0.341 to 1.791)
0.560
3+ 42 (18%) 261 (38%) 2.429
(1.117 to 5.284)
0.025 1.445
(0.587 to 3.555)
0.424
≥ 4 13 (5%) 91 (13%) 2.739
(1.111 to 6.751)
0.029 0.974
(0.334 to 2.840)
0.961
Global test < 0.001 0.045
Laboratory tests
Haemoglobin (g/l) 909 11.8 (1.1) 12.0 (1.4) 1.096
(0.983 to 1.223)
0.100 1.019
(0.885 to 1.173)
0.792
Platelet count
(× 109/l)
905 244 (77) 220 (77) 0.996
(0.994 to 0.998)
< 0.001 0.998
(0.996 to 1.001)
0.128
Log-transformed
ALT concentration
870 2.7 (0.6) 3.0 (0.8) 1.641
(1.244 to 2.165)
< 0.001 1.330
(0.958 to 1.848)
0.089
Log-transformed
serum uric acid
concentration
781 –1.3 (1.2) –1.0 (0.7) 1.409
(1.135 to 1.750)
0.002
continued
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hypertension, diabetes mellitus, autoimmune disease, renal disease or a history of pre-eclampsia in
previous pregnancies reduced the odds of composite adverse fetal outcomes for one pre-existing medical
complication (OR 0.65 95% CI 0.44 to 0.98) and for two or more pre-existing medical complications
(OR 0.43 95% CI 0.25 to 0.77).
The odds of fetal complications were significantly increased in women with raised urine PCR (OR 1.29,
95% CI 1.11 to 1.50), serum urea concentration (OR 1.72, 95% CI 1.07 to 2.76), treatment with
antihypertensives (OR 1.56, 95% CI 1.04 to 2.37), treatment with magnesium sulphate (OR 2.40, 95% CI
1.04 to 5.57), abnormal uterine artery Doppler (OR 1.94, 95% CI 1.08 to 3.51) and when expected fetal
weight was less than the 10th centile by ultrasound (OR 2.54, 95% CI 1.46 to 4.40).
TABLE 29 Crude univariable and multivariable analyses of candidate predictors and adverse fetal outcomes in
women with early-onset pre-eclampsia (continued )
Candidate
predictors Women, na
No adverse
fetal
outcomes
(n= 243),
mean (SD) or
n (%)
Adverse fetal
outcomes
(n= 702),
mean (SD) or
n (%)
Univariable
analysis (N= 945)
Multivariable
analysis (N= 945)
OR (95% CI) p-value OR (95% CI) p-value
Log-transformed
serum urea
concentration
876 1.2 (0.4) 1.4 (0.5) 3.679
(2.482 to 5.452)
< 0.001 1.718
(1.068 to 2.764)
0.026
Log-transformed
serum creatinine
concentration
908 4.0 (0.3) 4.1 (0.3) 2.823
(1.662 to 4.795)
< 0.001 1.039
(0.506 to 2.135)
0.916
Log-transformed
PCR
837 3.9 (1.4) 4.9 (1.4) 1.569
(1.397 to 1.762)
< 0.001 1.290
(1.111 to 1.497)
0.001
Treatment provided
Antihypertensive
therapy
944 177 (73%) 573 (82%) 1.663
(1.182 to 2.339)
0.004 1.558
(1.026 to 2.368)
0.038
Magnesium
sulphate
administered
944 9 (4%) 135 (19%) 6.190
(3.100 to 12.363)
< 0.001 2.402
(1.036 to 5.573)
0.041
Steroids
administered
783 66 (41%) 364 (59%) 2.186
(1.549 to 3.085)
< 0.001 1.208
(0.795 to 1.835)
0.376
Ultrasound and CTG
Uterine artery
Doppler abnormal
339 12 (14%) 79 (31%) 2.365
(1.536 to 3.639)
< 0.001 1.944
(1.077 to 3.510)
0.027
CTG findings
abnormal
710 10 (6%) 36 (7%) 1.395
(0.680 to 2.865)
0.364 0.625
(0.254 to 1.538)
0.306
Estimated fetal
weight
< 10th centile
712 27 (15%) 261 (49%) 3.835
(2.453 to 5.995)
< 0.001 2.538
(1.462 to 4.405)
0.001
Liquor volume
abnormal
890 10 (4%) 46 (7%) 1.548
(0.776 to 3.087)
0.215 1.279
(0.519 to 3.152)
0.593
OR, odds ratio.
a Descriptive of predictors based on the original non-imputed data. N is the number of women with available data.
Reproduced from Thangaratinam S, Allotey J, Marlin N, Dodds J, Cheong-See F, von Dadelszen P, et al. Prediction of
complications in early-onset pre-eclampsia (PREP): development and external multinational validation of prognostic models.
BMC Med 2017;15:68. This article is distributed under the terms of the Creative Commons Attribution 4.0 International
License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any
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Chapter 8 Discussion
In women with early-onset pre-eclampsia, the PREP prediction models provide robust estimates of theoverall risk of adverse maternal outcomes by discharge, and the risks at various time points following
diagnosis. The PREP-L model showed good discrimination and calibration and appeared to be useful in
predicting risk of complications as a result of early-onset pre-eclampsia in pregnancy and until discharge
for UK populations. Given that the rPREP-L model was easily transportable, with good performance in
the non-UK populations, we expect the original PREP-L model to have similar performance externally.
The PREP-S model showed good discrimination in external data sets, with reasonable calibration. The
use of this model will be useful to health-care professionals in deciding on the appropriate setting for
management and for commencement of interventions, such as steroids, if preterm delivery is anticipated.
Strengths and limitations
A well-performing prediction model is one that is relevant, accurate, validated in populations and data sets
external to those used to develop the model and applicable to clinical practice. With these properties,
it has the potential to improve clinical outcomes by helping clinicians and patients make more informed
decisions.
The PREP models were developed in a sample of women with early-onset pre-eclampsia, a condition that is
considered to be pathophysiologically different from late onset disease,8–10 and with a high proportion of
adverse outcomes. We used prospective cohorts with high-quality data for both model development and
validation, and with standardised definitions of variables and outcomes. The model was developed with
data from 53 units in the UK, making the results as generalisable as possible within the NHS.
We ensured that all routinely performed tests in clinical practice were evaluated. The choice of predictors
and components of the composite outcome were made by using Delphi surveys of experts in the field.9,15,41
We chose delivery before 34 weeks as an outcome to further minimise treatment paradox-related bias,
as delivery is planned at this gestation only if there are concerns regarding the health of the mother.
Prediction models often evaluate a large number of predictors in a population with few events, making the
findings less robust. We ensured that we had adequate sample size for the number of candidate predictors
to avoid overfitting.43–45 The rates of follow-up were very high in our PREP cohort and very few individuals
had missing values for most predictors.
One of the main reasons why clinicians lack confidence in applying risk scores in practice is the lack of
sufficient evidence to demonstrate the reproducibility and transportability of the model in an external data
set.32 Furthermore, they are less likely to accept the model if it does not include important predictors such
as BP. Guided by an a priori expert workshop (see Chapter 2, Analysis plan development), we minimised
bias due to treatment by the inclusion of management decisions such as use of antihypertensives and
magnesium sulphate as predictors. We transparently reported the development of the model and have
provided the regression coefficients to enable clinical use and future validation of the model.
Our prediction study used rigorous statistical methods to develop the model, to assess its accuracy and to
formally validate its performance in external data sets.32–35,39,48–51 We developed two prediction models for
the dual purpose of obtaining overall complication risks arising from pre-eclampsia and risk estimates
for complications at various time points after diagnosis. A logistic model alone would not have sufficient
sample size to provide estimates of adverse outcomes at time points close to diagnosis, such as 48 hours
after delivery, given the low rates of serious complications. However, the PREP-S model allowed us to
overcome this problem, and is the first to provide individualised risks of adverse maternal outcomes at
various time points after the diagnosis of early-onset pre-eclampsia.
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We performed geographic, temporal and domain validation of the model. The external data sets of the
PIERS and PETRA cohorts were geographically different (Canada and the Netherlands) and were conducted
earlier than the PREP study. We validated reduced models in external data sets as fewer predictors were
evaluated therein. However, the rPREP-L model validated with good discrimination and calibration for
predicting overall risk, and we expect the original PREP-L model to have similar, if not better, performance
if fully externally validated.
The aim of the model was to provide reliable, accurate and precise information of risks to the mother and
baby based on tests done at the time of diagnosis of early-onset pre-eclampsia. We only evaluated the
tests and variables measured routinely in clinical practice. The added value of biomarkers and ultrasound
to the accuracy of the model is not known. We refrained from using predictors such as fetal weight
estimated by ultrasound, which may have been a significant predictor, as access to ultrasound may not
always be available close to the diagnosis of pre-eclampsia in most units. We arbitrarily chose the
components of relevant medical history and scored them. Inclusion of a different set of medical conditions
may have altered the results. Women with a medical history score appeared to have a reduction in the risk
of complications. It is likely that specialists in joint obstetric specialist clinics closely monitor these mothers
resulting in early diagnosis of pre-eclampsia. Targeted and intense follow-up of these women may have led
to prolongation of pregnancy beyond 34 weeks and with low complications. When developing our PREP
models, we were unable to properly examine serum uric acid concentration as a predictor because at
the time of the model development there was a coding error in the data for this variable. However,
subsequent to the PREP models being developed and this coding error being corrected, we examined if the
inclusion of serum uric acid concentration was important and found that the c-statistic barely changed for
either the PREP-L or PREP-S model.
Women with earlier diagnosis of pre-eclampsia appeared to be at lower risk of maternal complications in
the PREP-S model. This is likely, as the primary outcome is largely driven by delivery before 34 weeks.
In women who were close to 34 weeks’ gestation, clinicians may have a lower threshold for delivery in the
next few days or weeks. However, if the diagnosis was made much earlier in the pregnancy, clinicians
would aim to prolong gestation as long as possible, leading to a longer survival time.
Our primary outcome was a composite of maternal complications. A different choice of outcomes may
have identified a different set of predictors. However, given the rarity of individual complications in women
with early-onset pre-eclampsia, we felt that our approach to include delivery before 34 weeks is a close
representative measure for the severity of the disease. However, we did not separately report iatrogenic
preterm deliveries from spontaneous preterm deliveries. As it is difficult to accurately identify the cause of
spontaneous preterm delivery, which could still be related to pre-eclampsia such as small abruption, we
grouped them together as one outcome.
The external data sets were limited in the number of variables evaluated, and hence we were unable to
validate our full PREP model in either of them. The reduced PREP models, especially rPREP-L, showed
good performance in the development and validation data sets, although the rPREP-S model showed
reduced performance. Although the overall values of predictors may be similar to the PREP cohort, the
management of women with early-onset pre-eclampsia may be different in the various health-care systems
of the external cohorts; for example, magnesium sulphate treatment was provided in 51% of all women
with early-onset pre-eclampsia in the PIERS cohort, compared with only 15% in the PREP cohort.
Furthermore, the variation in the proportion of women giving birth before 34 weeks’ gestation, which was
the major component of the composite outcome, may have contributed to the reduced performance of
the model in the external data sets. The narrow spectrum of diseases in individuals in the PETRA cohort
may have contributed to the reduced performance of the PREP model.
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Comparison with existing evidence
So far, systematic reviews have not been able to produce robust estimates of accuracy of the individual
tests.20,22,23,39,53,54 Tests widely used in clinical practice, such as measurement of BP and proteinuria, suffered
from treatment paradox and those such as clonus and deep-tendon reflexes were not studied in sufficient
detail. This study is the first to address the above deficiencies.
The PREP study is the first to develop and validate the models for predicting adverse maternal outcomes
specifically in women with early-onset disease. Previously, the PIERS and mini-PIERS models have provided
estimates for overall risk of adverse outcomes in women with pre-eclampsia of any onset. Their sample
sizes were too small to predict complications in women with early-onset pre-eclampsia. This is also the
first study to provide individualised risk estimates for adverse outcomes at various time points after
diagnosis of early-onset pre-eclampsia. Although the PIERS model included predictors such as gestational
age at diagnosis, and concentrations of liver enzymes (AST) and serum creatinine to predict a composite
maternal outcome, other important variables, such as BP and proteinuria, were not included.
The performance of any prediction model is influenced by effective treatment measures, such as
antihypertensive drugs, magnesium sulphate and delivery, which reduces the probability of adverse
outcomes. To avoid such bias, we included management strategies such as need for antihypertensive
drugs and magnesium sulphate as predictors. Furthermore, as delivery is considered to be the cure for
the condition, we incorporated preterm delivery before 34 weeks’ gestation as a component of the
maternal composite adverse outcome. We considered early preterm delivery to be indicative of the severity
of the condition, as clinicians usually aim to prolong pregnancy beyond 34 weeks’ gestation to reduce
prematurity-related complications in the neonate unless there are overwhelming concerns about the health
of the mother. This approach has led to the inclusion of important tests such as measurement of BP,
proteinuria and the need for antihypertensives and magnesium sulphate as significant predictors in the
final PREP models.
To ensure that the prediction model could be applied in clinical practice, the findings at the time of
baseline (i.e. at diagnosis) should be used to assess the risk. Many models include the worst value of
the predictor in the same time period used for outcome ascertainment. This is likely to overestimate the
predictive performance of the model. Rule of thumb indicates that at least 10 events should be available
per candidate predictor for model development. Compared with the PIERS model, that evaluated
34 predictors for 106 outcomes at 48 hours, the survival analysis approach taken with the PREP-S model
allowed us to have sufficient sample size to predict complications accurately at various time points,
including 48 hours after diagnosis. The PIERS model did not provide estimates of overall risk of
complications in pregnancy and reported a discrimination index of just > 0.7 for prediction of adverse
outcomes by 1 week. The PREP-L model showed good discrimination of > 0.8 to predict overall risk until
discharge and the PREP-S model had an estimate of > 0.75. The performance validated well in the external
data set with good discrimination and calibration. Given the potentially rapid changes in predictor values
over time in pregnancy, these measures are impressive for their predictive power at the time of diagnosis
of the condition.
Implications for clinical practice
The PREP models were developed with the explicit purpose of providing relevant information to mothers
and clinicians on individualised risks at the time of diagnosis of pre-eclampsia. The Microsoft Excel file is
user-friendly and easily accessible. It should be emphasised that the PREP models should not be used to
choose between administration or non-administration of antihypertensives and magnesium sulphate,
which are predictor variables. The risk estimates provided by the model are relevant to women who are
managed as per the current clinical guidelines.55 For example, when managing women admitted with very
high BP, the clinicians are expected to manage the mother as per current guidelines with antihypertensives
DOI: 10.3310/hta21180 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 18
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Thangaratinam et al. under the terms of a commissioning contract issued by the Secretary of State
for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
63
and, if appropriate, magnesium sulphate, and not to base treatment on the probability of risk provided
by the model. However, the PREP-S model will be useful in providing the mother’s individualised risk of
adverse outcomes at various time points, such as 48 hours after diagnosis, given the clinical characteristics
and the choice of treatment.
The PREP-L model provides mothers with the overall risk of experiencing an adverse outcome by the time
of discharge. The PREP-L model had high discrimination and calibration estimates in both development and
validation data sets, and thus appears accurate and transportable to the non-UK populations examined.
Clinicians and mothers should be informed that the model provides overall risks by discharge and should
not be used to plan immediate management.
The calibration of the PREP-S model was good in the development data set, as expected, and reasonable
in the validation cohort, especially for those with high risk, which suggests that women deemed to be at
high risk of outcomes are also more likely to experience the outcome. The PREP-S model can be used as a
tool for triaging mothers with a diagnosis of pre-eclampsia before 34 weeks’ gestation to decide on the
optimal place of delivery. In women identified as high risk by the model, efforts should be made for early
transfer of the mother to a tertiary unit for neonatal care, in addition to care for the mother. As the tool
provides risk estimates at various time points, resources can be mobilised appropriately when required
for transfer of the mother. The risk estimates will identify mothers who require prophylactic corticosteroids
when preterm delivery is anticipated. In addition, this tool will allow neonatologists to provide
individualised prognostic estimates for the baby after delivery, depending on the predicted risk of
complications and for that gestational age.
Research recommendations
The PREP models assessed the risk of composite adverse outcomes. Individual patient data meta-analysis
of the studies evaluating the prediction of the accuracy of tests for complications would provide an
increased sample size to assess the risk of individual outcomes or outcomes grouped by the organ system
involvement. We have undertaken the first two stages (model development and external validation) in
prognostic research aimed at improving patient care. A final evaluation of the impact of PREP models on
clinical practice is required, especially in the improvement of health outcomes for the mother and baby,
but is beyond the remit of this project. In other words, further research may examine the impact of
implementing the PREP-S and PREP-L models into clinical practice, in terms of their uptake by clinicians and
their impact on patient outcomes. This might be in the form of a cluster randomised trial, for example,
with practices randomised to either using or not using the PREP-S and PREP-L models.
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Appendix 1 Prioritisation of outcomes for
inclusion in the composite adverse maternal outcome
based on clinical importance by expert panel
Outcome Score Median Range Ranking
Transfusion of blood products 11 1 1–2 Mild
Bell’s palsy 12 1 1–2 Mild
Postpartum haemorrhage > 1 l 15 2 1–3 Moderate
Hepatic dysfunction 15.5 2 1–3 Moderate
Acute renal insufficiency 17 2 1–3 Moderate
Positive inotrope support 18 2 1–3 Moderate
Requirement for > 50% oxygen for > 1 hour 18 2 1–3 Moderate
Posterior reversible encephalopathy 20.5 2 2–3 Moderate
Reversible ischaemic neurological deficit 21 2 2–3 Moderate
Hepatic haematoma 22 2 2–3 Moderate
Intubation 22 3 2–3 Severe
Glasgow coma scale score of < 13 23 3 2–3 Severe
Pulmonary oedema 23 3 2–3 Severe
Abruptio placentae 23 3 1–3 Severe
Retinal detachment 24 3 2–3 Severe
Eclamptic seizures 25 3 2–3 Severe
Cortical blindness 26 3 3–3 Severe
Stroke 26.5 3 3–3 Severe
Maternal mortality 27 3 3–3 Severe
Hepatic rupture 27 3 3–3 Severe
Dialysis 27 3 3–3 Severe
Myocardial ischaemia/infarction 27 3 3–3 Severe
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Appendix 2 Changes since original application
What was proposed in original grant application What was done in the PREP study
The original target sample size was 500 women with
confirmed diagnosis of pre-eclampsia
The sample size was revised so we continued recruitment until
100 women had experienced an adverse event. The population
did not change
Update on maternal predictor variables Chest pain and dyspnoea were added as candidate predictors.
Gestational age, maternal age and platelet count were also
added to the maternal prognostic factors
One general list of candidate prognostic factors Candidate prognostic factors were split into maternal and fetal
predictor variables and only the fetal predictor variables
included ultrasound
Symptoms of headache, epigastric pain, nausea, chest
pain, dyspnoea or visual disturbance were one variable
These were split and regrouped into:
1. symptoms of headache and visual disturbance
2. epigastric pain and nausea
3. chest pain and dyspnoea, forming three variables relating to
a particular body system
BP was one variable This was split into systolic BP and diastolic BP
Outcome assessment by 48 hours and by discharge For the logistic model we had insufficient sample size to assess
model performance at 48 hours. Therefore, we developed a
second model, the survival model, to provide risks at various
time points including 48 hours. However, we censored at
34 weeks, as one of the components of the outcome is delivery
by 34 weeks
Develop the PREP model in the ASTRONAUT cohort
of women
The ASTRONAUT study (gtr.rcuk.ac.uk/projects?ref=G0601295)
did not commence and we were therefore unable to work on
its data
Validate the PREP model in the PIERS and PETRA cohort We validated the rPREP-L model in both external data sets. We
were unable to validate the rPREP-S model in the PETRA data
set; dates and times of outcome occurrence were not reported
Assess the added predictive contribution of biomarkers
(sFlt1, sEng, PIGF) in maternal blood or urine
The ASTRONAUT study, planned to provide data on biomarkers,
did not commence and we were therefore unable to work on
its data
Update of maternal outcomes Platelet count and infusion of any third parenteral
antihypertensive removed as maternal outcomes. Preterm
delivery < 34 weeks’ gestation added as a maternal outcome
ASTRONAUT, Angiogenic biomarkerS as predictive Tests for early ONest pre-eclampsia: a population based sTudy;
PIGF, placental growth factor; sEng, soluble endoglin; sFlt1, soluble fms-like tyrosine kinase-1.
Reproduced from Thangaratinam S, Allotey J, Marlin N, Dodds J, Cheong-See F, von Dadelszen P, et al. Prediction of
complications in early-onset pre-eclampsia (PREP): development and external multinational validation of prognostic models.
BMC Med 2017;15:68. This article is distributed under the terms of the Creative Commons Attribution 4.0 International
License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any
medium, provided that appropriate credit to the original authors and the source is given.40
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Appendix 3 PREP-L model
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Appendix 4 PREP-S model
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Appendix 5 Multivariable fractional polynomial
terms that best predict outcome in the logistic model
Multiple imputation data set Variables Best powers identified p-value
1 Maternal age (years) 1 0.782
Log-transformed gestational age at diagnosis 3 3 < 0.001
Systolic BP (mmHg) 1 0.788
Platelet count (× 109/l) 1 0.250
Log-transformed serum urea concentration –1 0.002
Log-transformed PCR 1 0.261
2 Maternal age (years) 1 0.835
Log-transformed gestational age at diagnosis 3 3 < 0.001
Systolic BP (mmHg) 1 0.761
Platelet count (× 109/l) 1 0.176
Log-transformed serum urea concentration –1 0.003
Log-transformed PCR 1 0.202
3 Maternal age (years) 1 0.821
Log-transformed gestational age at diagnosis 3 3 < 0.001
Systolic BP (mmHg) 1 0.682
Platelet count (× 109/l) 1 0.177
Log-transformed serum urea concentration –1 0.002
Log-transformed PCR 1 0.364
4 Maternal age (years) 1 0.799
Log-transformed gestational age at diagnosis 3 3 < 0.001
Systolic BP (mmHg) 1 0.653
Platelet count (× 109/l) 1 0.219
Log-transformed serum urea concentration –1 0.001
Log-transformed PCR 1 0.462
5 Maternal age (years) 1 0.958
Log-transformed gestational age at diagnosis 3 3 < 0.001
Systolic BP (mmHg) 1 0.684
Platelet count (× 109/l) 1 0.288
Log-transformed serum urea concentration –1 0.007
Log-transformed PCR 1 0.342
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Appendix 6 Coefficients of the final multivariable
logistic model after adjustment for optimism
Predictor Coefficient
Maternal age (years) –0.020
FP (log-GA at diagnosis)3 centred at 39.90241 12.047
FP (log-GA at diagnosis)3 × ln(log-GA at diagnosis) centred at 49.08188 –7.926
Effect of a medical history score of 1 –0.330
Effect of a medical history score of ≥ 2 –0.579
Systolic BP (mmHg) 0.024
Platelet count (× 109/l) –0.004
FP (log-serum urea concentration)–1 –0.950
Log-transformed PCR 0.146
Baseline treatment: any antihypertensive drug 0.409
Baseline treatment: magnesium sulphate 1.252
Constant –1.507
GA, gestational age.
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Appendix 7 Comparison of the flexible
parametric approach with the Cox model for the full
survival model
Candidate predictors
Flexible parametric model after
multiple imputation
Cox regression after
multiple imputation
Hazard ratio (95% CI) p-value Hazard ratio (95% CI) p-value
Maternal age (years) 0.968 (0.954 to 0.982) < 0.001 0.967 (0.954 to 0.982) < 0.001
Log-transformed gestational age (weeks)
at diagnosis
22.425 (8.528 to 58.970) < 0.001 21.552 (8.156 to 56.952) < 0.001
Symptoms of headache and/or visual
disturbance
1.007 (0.835 to 1.215) 0.940 1.004 (0.832 to 1.211) 0.968
Symptoms of epigastric pain, nausea
and/or vomiting
0.943 (0.745 to 1.194) 0.627 0.942 (0.744 to 1.192) 0.618
Symptoms of chest pain and/or dyspnoea 1.172 (0.766 to 1.793) 0.465 1.183 (0.771 to 1.813) 0.442
Clonus 0.763 (0.547 to 1.064) 0.111 0.763 (0.545 to 1.068) 0.115
Exaggerated tendon reflexes 1.249 (0.996 to 1.566) 0.054 1.261(1.004 to 1.584) 0.046
Medical history score (reference 0)
Effect of a medical history score of 1 0.828 (0.671 to 1.022) 0.078 0.831 (0.673 to 1.025) 0.084
Effect of a medical history score of 2 0.658 (0.479 to 0.905) 0.010 0.660 (0.480 to 0.908) 0.011
Twins vs. singleton 0.895 (0.631 to 1.270) 0.535 0.904 (0.637 to 1.283) 0.571
Triplets vs. singleton 1.194 (0.291 to 4.904) 0.806 1.177 (0.287 to 4.836) 0.821
Systolic BP (mmHg) 1.018 (1.012 to 1.024) < 0.001 1.017 (1.012 to 1.023) 0.000
Diastolic BP (mmHg) 1.002 (0.993 to 1.011) 0.695 1.002 (0.993 to 1.011) 0.677
Oxygen saturation < 94% 4.342 (1.496 to 12.607) 0.007 4.514 (1.557 to 13.088) 0.006
Haemoglobin level (g/l) 1.051 (0.984 to 1.121) 0.137 1.053 (0.986 to 1.124) 0.123
Platelet count (× 109/l) 0.997 (0.996 to 0.998) < 0.001 0.997 (0.996 to 0.998) < 0.001
Log-transformed ALT concentration 1.181 (1.040 to 1.341) 0.010 1.179 (1.038 to 1.340) 0.011
Log-transformed serum uric acid
concentration
1.052 (0.957 to 1.157) 0.289 1.051 (0.956 to 1.155) 0.302
Log-transformed serum urea
concentration
1.555 (1.296 to 1.865) < 0.001 1.558 (1.300 to 1.868) < 0.001
Log-transformed serum creatinine
concentration
1.549 (1.081 to 2.219) 0.017 1.549 (1.080 to 2.220) 0.017
Urine dipstick (reference: none/trace)
1+ 0.864 (0.522 to 1.433) 0.572 0.855 (0.516 to 1.417) 0.544
2+ 0.994 (0.619 to 1.597) 0.981 0.987 (0.614 to 1.585) 0.956
3+ 1.293 (0.795 to 2.103) 0.300 1.282 (0.789 to 2.085) 0.316
≥ 4 1.216 (0.717 to 2.062) 0.469 1.200 (0.707 to 2.036) 0.499
Log-transformed PCR 1.082 (1.001 to 1.169) 0.047 1.084 (1.004 to 1.170) 0.040
Baseline treatment
Any antihypertensive drug 1.239 (0.983 to 1.562) 0.070 1.231 (0.976 to 1.552) 0.079
Magnesium sulphate 3.540 (2.708 to 4.627) < 0.001 3.523 (2.693 to 4.609) < 0.001
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Appendix 8 Coefficients of the survival model
after adjusting for optimism
Predictor Coefficient
Maternal age (years) –0.031
FP (log(GA at diagnosis/10))–2 centred at 0.8345136 1.514
FP (log(GA at diagnosis/10))–2 × ln(log(GA at diagnosis/10)) centred at 0.0652155 5.707
Exaggerated tendon reflexes 0.122
Summary score of medical history
Effect of a medical history score of 1 –0.169
Effect of a medical history score of ≥ 2 –0.385
Systolic BP (mmHg) 0.016
Pulse oximetry < 94% 0.797
Platelet count (× 109/l) –0.002
Log-transformed ALT concentration 0.126
FP (log-serum urea concentration)2 0.605
FP (log-serum urea concentration)3 –0.144
Log-transformed serum creatinine concentration centred at 0.4067578 0.265
Log-transformed PCR 0.080
Baseline treatment
Any antihypertensive 0.176
Magnesium sulphate 1.066
Baseline H(t) terms
Spline basis function 1 1.500
Spline basis function 2 –0.116
Spline basis function 3 0.141
Spline basis function 4 –0.054
Spline basis function 5 –0.011
Constant –3.724
GA, gestational age; H(t), hazards at time.
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Appendix 9 Coefficients of the final adapted
PREP-L model adjusted for optimism excluding serum
urea concentration
Predictor variables Coefficient
Maternal age (years) –0.020
FP (log-GA at diagnosis)3 centred at 39.90241 11.386
FP (log-GA at diagnosis)3 × ln(log-GA at diagnosis) centred at 49.08188 –7.492
Summary score of medical history
Effect of a medical history score of 1 –0.340
Effect of a medical history score of ≥ 2 –0.518
Systolic BP (mmHg) 0.023
Platelet count (× 109/l) –0.005
Log-transformed PCR 0.203
Baseline treatment
Any antihypertensive 0.453
Magnesium sulphate 1.287
Constant –3.577
GA, gestational age.
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Appendix 10 Coefficients of the final adapted
PREP-S model adjusted for optimism and excluding
serum urea concentration, clonus and exaggerated
tendon reflexes
Predictor variables Coefficient
Maternal age (years) –0.029
FP (log(GA at diagnosis/10))–2 centred at 0.8345136 1.076
FP (log(GA at diagnosis/10))–2 × ln(log(GA at diagnosis/10)) centred at 0.0652155 4.635
Effect of a medical history score of 1 –0.188
Effect of a medical history score of ≥ 2 –0.339
Systolic BP (mmHg) 0.016
Oxygen saturation < 94% 1.587
Platelet count (× 109/l) –0.003
Log-transformed ALT concentration 0.141
Log-transformed serum creatinine concentration centred at 4.067578 0.669
Log-transformed PCR 0.138
Baseline treatment: any antihypertensive 0.178
Baseline treatment: magnesium sulphate 1.083
Spline basis function 1 1.455
Spline basis function 2 –0.090
Spline basis function 3 0.148
Spline basis function 4 –0.052
Spline basis function 5 –0.009
Constant –6.009
GA, gestational age.
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Appendix 11 PREP study data collection forms
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